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The endocrine pancreas exerts i ts key metabolic functions 
through a complex interactive endocrine units, dispersed over 
the entire pancreas. In search for the mechanism and factors 
responsible for normal and abnormal glucose homeostasis, pancreatic 
units, is lets of Langerhans have been the subject of study. At 
least four different islet cells have been distinguished, all of 
which exhibit the features of secretory cel ls . The hormones, 
insulin, glucagon and somatostatin have been identified respectively 
in B, A and D cells . Homeostatic regulation of metabolic fuels 
involves intricate balance in the secretion of islet hormones. Pot-
entially important regulatory factors for the secretory activity 
of islet cells appear highly dependent on various nutrients, hor-
mones, neurotransmitters, substrates and intrinsic response of the 
l iver (hepatic glucose autoregulation). 
Factors which govern the intracellular events in the endo-
crine pancreas remain poorly defined, like other t issues, islet mem-
brane regulate also cyclic AMP levels, which modulate B-cell funct-
ion. In addition, B-cell is equipped with glucoreceptor, nature 
and localization of which is s t i l l controversial. The glucose recog-
nition represents an important physiological event for the B-cell, 
crucial for the insulinotropic effect of other agents and capable 
_of inducing hormone synthesis , transport and release. Impairment 
in the secretory response of the B-cell appears a characterist ic 
feature of maturity onset diabetes. 
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Insulin is an anabolic hormone and coordinates the action 
of other hormones which are involved in intermediary metabolism 
such as thyroxine, growth hormone, glucagon, glucocorticoids, in-
volved in the utilization of food, thermogenesis and tissue main-
tenance. Insulin acts by binding to its target tissues and has 
stimulatory effect on glucose oxidation in target tissues. Insulin 
activates the synthesis of glycogen, l ipid , proteins, nucleic acids, 
within the cel ls . 
In the present studies (-)epicatechin was tested for its 
insulin like effects on target tissues ^n vi t ro . Nature of the binding 
site of (-)epicatechin on target cells have been studied by com-
125 petitive binding with I-insulin. Efforts have also been made 
to gain some knowledge about the effect of age on the islets isolated 
from different age group of rats in response to certain insulin 
secretagogues. Studies on the conversion of proinsulin to insulin 
and cathepsin B activity in islets of Langerhans have also been 
carried out. Coleonol, a diterpenoid, isolated from Coleus forskohlii 
was studied for i ts effect on blood glucose, serum free fatty acid 
level as well as on l iver glucose-6-phosphatase activity and glycogen 
level after oral feeding. In addition, insulinotropic action of chole-
cystokinin and its synthetic congeners were studied at stimulatory 
and non-stimulatory concentrations of glucose are presented in this 
dissertation. 
k 
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I. Insulin like activity In (-)cplcatechln 
(I) Effect of (-)epicatechin on oxygen uptake in tissues and fat 
cells in vitro 
At one millimolar concentration of (-)epicatechin, oxygen 
uptake increases significantly in fat cel ls , l iver, heart but not 
in brain tissues. The stimulation of oxygen uptake in different 
tissues and cells was blocked by sodium azide. 
(II) Effect of (-)epicatechin on incorporation of U -C glucose 
into glycogen In rat diaphragm and glycogen content ^n vitro 
(-)Epicatechin, when incubated with rat diaphragm causes 
~" 14 
an increase in glycogen content as well as incorporation of U -C 
glucose into glycogen of rat diaphragm ^ii vitro in a dose dependent 
14 
manner. Kinetic studies show that the incorporation of U -C glucose 
into glycogen of rat diaphragm is linear upto 1 hour. 
( i l l ) Effect of (-)epicatechln on lipolysis in epidymal fat pads 
In vitro 
Lipolysis induced by 1.5 mM theophylline in fat pads is 
inhibited (61%) in the presence of 1 mM (-)epicatechin as compared 
to 74% inhibition observed in the presence of 1 mU insulin. 
125 (iv) Effect of (-)epicatechln on the binding of I-insulln to 
the liver cell plasma membrane 
Competitive binding experiments between (-)epicatechin 
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and I-insulin, does not show any significant change in the binding 
125 
of I-insulin to the l iver membrane indicating that the insulin 
like properties of the flavonoid are not due to i ts sharing of the 
binding site with insulin. 
(iv) Effect of (-)epicatechln on islet cAMP content 
The effect of (-)epicatechin was studied in the presence 
of 2 and 20 mM glucose concentrations and 200, 400, 600,800 and 
1000 uM (-)epicatechin in the medium. (-)Epicatechin caused a 
significant and dose dependent increase in islet cAMP content both 
at 2 and 20 mM glucose concentration. 
(v) -Effect of age on (-)epicatechin stimulated insulin release from islets 
of Langerhans in vitro 
At stimulatory and non-stimulatory concentrations of glucose 
in medium, (-)epicatechin (1 mM) stimulated the release of insulin 
quite significantly. However, (-)epicatechin and glucose stimulated 
insulin release decreased with the increase of the animal's age. 
(vi) Effect of (-)epicatechin on cathepsin B activity in is lets of Langer-
hans in vitro 
Incubation of rat islets with 1 mM (-)epicatechin for 2 
hrs caused 2.26 fold stimulation in the islets cathepsin B activity 
over the control. 
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(vi i) (-)Epicatechin stimulated conversion of prolnsulin to insulin and 
effect of age thereon 
Incubation of islets of Langerhans in Kreb's Ringer bicar-
14 
bonate medium containing 50 uCi C-leucine, and subsequent fraction-
ation by passing through sephadex G-50 column (1.5x55 cm) gives 
distinct peaks of proinsulin (P) and insulin ( I ) . Prolnsulin was 
characterized by i ts conversion to insulin by cathepsin B, it was 
found that age has a pronounced effect on (-)epicatechin mediated 
transformation of proinsulin. The conversion of proinsulin to insulin 
in the case of 1 month old rats was found to be about 9% more 
as compared to the conversion in the case of 12 month old r a t s . 
II. Coleonol 
(i) Effect of coloenol on insulin release in vitro 
Coleonol enhances the release of insulin from islets of 
Langerhans jui vitro in the presence of 5.6 mM glucose in the medium, 
— while Tn the medium containing non-stimulatory concentration of 
glucose, no effect on insulin release has been observed. Stimulation 
of insulin release has been observed upto 3 uM concentration of 
coleonol. 
( i i ) Effect of coleonol on glucagon release in vitro 
Coleonol has been found to stimulate the release of glucagon 
from islets of Langerhans jri v i t ro . Stimulation of glucagon release 
is much higher than the release of insulin stimulated by coleonol 
in vi t ro . 
166 
( i i i ) Effect of coleonol feeding on serum insulin and glucagon level 
Coleonol feeding caused a significant increase in the serum 
insulin and glucagon levels. Increase in the serum glucagon level 
has been found to be much greater than the serum insulin level 
after coleonol feeding. 
(iv) Effect of coleonol on rat liver glycogen and gluconeogenic enzymes 
in vivo 
Feeding of coleonol in normal rats causes a significant 
depletion of l iver glycogen (40%) and increase in the activit ies 
of gluconeogenic enzymes (Glucose-6-phosphatase). 
(v) Effect of coleonol on oxygen-uptake by liver mitochondria 
CL-uptake studies in oxygraph show that feeding of coleonol 
increases CL-consumption by l iver mitochondria, showing an increased 
metabolic ra t . 
(vi) Effect of coleonol on islet enzymes in vivo 
Feeding of coleonol in normal rats causes a significant 
stimulation in the activity of islet gluconeogenic enzyme, glucose-
6-phosphatase and lysosomal enzyme, cathepsin B. 
III.CCK-4 
(i) Effect of synthetic analogues of C-terminal tetrapeptlde amide of 
cholecystoklnin on insulin and glucagon release from the islets 
in vitro 
The cholecystokinin stimulated the secretion of pancreatic 
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hormones in a dose-related manner. CCK-4 was by for the most 
potent peptide. Evan at the lowest concentration of 10" M, CCK-4 
was a powerful secretagogue. The synthetic peptides with C-terminal 
modifications such as removal of tryptophan (CCK-4), extension 
by glycine (CCK-5, gastrin pentapeptide) reduced the secretion 
of pancreatic hormones. Peptides with N-terminal modifications 
were synthesized by substitutions of L-Pro, ^ P r o , D-Pro or Thz 
(Thiazolidine-4-carboxylic acid) in place of Trp at position 1 of 
the CCK-4 molecule. 
Substitutions of L-Pro, <aPro and Thz at position 1 of CCK-4 
molecule reduced the insulin releasing activity of CCK-4 analogues 
as compared to CCK-4. However, these analogues have no effect 
on glucagon release. Substitution of D-Pro at position I of CCK-4 
molecule and N-methylation of Phe residue resulted in the stimu-
lation of insulin release and inhibition of glucagon release. 
(11) Effect of stimulatory concentration of glucose on CCK-4 and its 
analogues stimulated insulin and glucagon release in vitro 
CCK-4 and its synthetic analogues were found to be in-
creasing the release of insulin at basal as well as stimulatory 
concentrations of glucose. Synthetic analogues of CCK-4 were found 
to" have an additive effect on insulin release at stimulatory concent-
ration of glucose in the incubation medium. CCK-4 analogues (DPMAP 
8 LPMAP) have inhibitory effect on glucagon release at 20 mM glucose, 
8 
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Effect of age on CCK-4 stimulated release of insulin from Islets 
of Langerhans in vitro 
At basal concentration of glucose in the medium insulin 
release from 1 and 12 months old rat islets was not significantly 
different. However, aged rat islets released less insulin in res-
ponse to CCK-4, DPMAP 5 LPMAP compared to that from younger 
ones. 
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PREFACE 
The great breakthrough in the understanding of diabetes 
was the demonstration that acute diabetes followed pancreatectomy. 
Thereafter, the isolation and purification of insulin brought life 
to diabetics who, without it, faced death. Pancreatic islets of 
Langerhans represent a unique cluster of different types of cellular 
populations responsible for the biosynthesis and release of their 
characteristic hormones. Coordinated regulation in the release 
of these hormones is vital for the maintenance of a proper metabolic 
status of the body, especially the homeostasis of glucose. Thorough 
knowledge of the islets and the functions of its various cell types 
i s , therefore, a must for understanding the mechanism through 
which a well balanced interaction of various peptide hormones 
of the islets brings about this delicate and vital biological effect. 
Any defect in the functioning of the islet cells is manifested in 
the form of imbalance in glucose homeostasis and, in many cases, 
develops into diabetic syndrome, the etiology and pathogenesis 
of which st i l l remains to be fully elucidated. Sensitivity of the 
islet cells towards various secretagogues and the effect of other 
factors on the i s l e t ' s hormone release has been a subject matter 
for intensive research during the last more than two decades. 
In this dissertation, attempts have been made to contribute 
towards the efforts in the direction of developing new hypoglycemic 
drugs for the management of type II diabetes. Attempts have also 
i i 
been made to have some insight into the age related changes in 
the islet cells with respect to their sensitivity towards secreta-
gogues. Some interesting properties of new synthetic analogues 
of C-terminal tetrapeptide amide of cholecystokinin indicating their 
potentiality to be effective hypoglycemic drugs have been presented. 
New findings on insulin like properties of (-)epicatechin and its 
effect on the conversion of proinsulin to insulin and the effect 
of age of the animal thereon are some of the highlights of the 
studies presented in this disseration. 
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REVIEW OF LITERATURE 
1 
HISTORICAL 
The s i g n i f i c a n c e of the d i s c o v e r y of i s l e t s of 
Langerhans in 1869, had been recognized only after 20 years when 
Oskar Minkowsky 8 Joseph Von Mering showed in 1889 that total 
pancreatectomy in the dog produced symptoms indistinguishable 
from Type I (insulin dependent) diabetes in man. The experiment, 
which was a remarkable surgical feat at the time, was actually 
initially designed to resolve a dispute between the authors as 
to whether the pancreas was involved in lipid digestion (Housay, 
1952). Minkowski, the junior member of the team, then in his 
early th i r t ies , noticed that the house trained animal could no 
longer control its bladder. This lead him to make the crucial 
determination of urinary sugar. These investigations opened the 
way to the study of diabetes in experimental animals and shifted 
the focus away from diabetes as a disease of the organism to a 
disease affecting a particular organ. The link between the metabolic 
function of the pancreas identified by Von' Mering and Minkowski 
and the islets of Langerhans was finally established by the work 
of Opie on human diabetic pancreases at the beginning of the 
twentieth century (1901). Progress towards understanding the secret-
ion of insulin at the level of the is le ts , however, was impeded 
until techniques for the isolation of islets from experimental animals 
were introduced in the middle sixties by Hellerstorm (1964); 
Mosaklewski (1965) 8 Lacy et al . (1967). 
2 
ISLETS OF LANGERHANS 
The islets of Langerhans are complex, interactive endocrine 
units in a supporting matrix of connective tissue with a rich vas-
cular network. The endocrine pancreas of normal adult rat consti-
tute 1-2 percent of total pancreatic mass, consisting of approximately 
2000 islets of Langerhans (Hellman, 1959) with a mean diameter 
of 100-200 urn (range 50-300 urn) (Hellman et_ a\_., 1964; Henderson, 
1969; Zimmy 5 Blackard, 1975). They are recognizable as spherical , 
ovoid, elliptical or irregular aggregates of cells (Green 8 Taylor, 
1972). 
Cellular composition of the endocrine pancreas: 
Histological, immunocytochemical and ultrastructural studies 
have demonstrated that human or rat islets are composed of 70-
80 percent insulin producing beta cells that reside largely in the 
interior of the islet , 15-20 percent glucagon producing A cells 
or pancreatic polypeptide containing PP-cells arranged in the peri-
phery and 5-10 percent somatostatin containing D-cells that are 
dispersed throughout the is le ts . This morphological arrangement 
consisting of a central core of beta cells may be functionally impor-
tant for the component endocrine cells to modulate their hormone 
release. 
Staining techniques for identification of islet cells: 
Several excellent staining techniques exist for the demons-
tration of the beta-cells in preparation for light microscopy, namely 
3 
chromium hematoxylin and aldehyde fuchsin procedures of Gomori 
(1939, 1941. 1950), the Victoria Blue method of Ivic (1959) and 
the pseudoisocyanine technique of Schiebler and Schiessler (1969). 
For the demonstration of A and D cells , these methods are less 
satisfactory since in the Gomori procedures both A and D-cells 
are stained in red with phloxine. To distinguish between these 
two types of non B-cells, a thricrome staining can be used (Bencosme, 
1952; Lazarus fi Volk, 1962). 
A wide variety of silver impregnation techniques has also 
been applied to the endocrine pancreas to demonstrate non B-cells 
more distinctly. Creutzfeldt (1953) and Gepts (1957) argued that 
the Gros-Schultze as well as Holmes procedure, do not only stain 
all non B-cells, but a variable number of B-cells as well. Hellerstorm 
and Hellman (1960) claimed that with their modification of the 
Davenport technique, less A-cells are stained than with the Gomori 
methods. They called A.-cells , those cells that did take up silver 
and A2-cells those that remained unstained. The four types of 
cells were called: A,B,C and D cells (Deconinck et^  al_. , 1971; 
1972). It was pointed out that cells equivalent to D and D. cells 
are normally present in the gastroduodenal mucosa. Recently it 
was reported that cells identical to pancreatic A cells also occur 
in the same mucosa in some species (Unger S Orci, 1975; Dobbs 
et a l . , 1975; Larsson ej_ al_. , 1975), B-cells on the other hand 
have never been detected in the gut mucosa of mammals. 
4 
Separation and isolation of islet cell types: 
Islet B-cells can be separated on the basis of their Larger 
size (Pipeleers ej^  aL , 1979, 1981) by flow cytometry with cellular 
light scatter activity as separation parameter. Light scatter acti-
vity alone separates poorly islet and non B-cells and can, 
therefore, not be adequately used for their isolation (Van De Winkel 
M et_ aL , 1982a; Pipeleers. 1984). Differences in cell density 
can be employed to purify glucagon containing A-cells from islet 
cell preparations which are alrn-idy enriched in islet non B-cells, 
(Pipeleers ej_ aL , 1981). Isopycnic gradient centrifugation of 
elutriated islet non B-cells yields preparations with more than 
90%. A-cells between densities 1.067 and 1.07 g/ml but the final 
cell yield is less than 20% (Pipeleers e^ a L , 1981). 
Isolation of islet and non B -cells led to the availabili ty 
of circulating - islet cell surface antibodies (ICSA) which bind 
to the insulin containing B -cells and not to the other islet cell 
types (Van de Winkel e_t_ aL , 1982b). These IgG antibodies were 
primarily detected in Type-I (insulin dependent) diabetic patients 
younger than 30 years of age (Van de Winkel et_ a L . 1982b). 
ICSA have been used to fluorescently label the islet B-cells, so 
that they become separable by fluorescence-activated cell sorting 
(Van de Winkel e_t_ aJL . 1982b). Monoclonal antibodies binding 
selectively to B -cells have also been employed for this purpose 
(Alejandro et al . , 1984 5 Russel et a L , 1984). 
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The endogenous fluorescence of the cells was found to 
be a most useful parameter for the purification of islet cells 
(Pipeleers et al_. , 1985; Van de Winkel et_ al_., 1982). In addition 
to yielding highly purified islet cell suspensions, autofluoresconce-
activated cell sorting offers the advantage of preparing cells free 
of exogenous ligand. It also provides a method to distribute the 
cells according to their functional activities (Van De Winkel S 
Pipeleers, 1983; Pipeleers e_t_ aj_. , 1987). The technique takes 
advantage of the ubiquitous presence of the autofluorescent flavin 
and pyridine nucleotides (Aubin, 1979; Benson £t_ aj_. , 1979). At 
2.8 m mol/ L glucose, the cell population with low FAD values 
consists of more than 95% single B-cells (Pipeleers e\_ a\_. , 1985a; 
Van De Winkel e_t_ aj^ . , 1982). If isolated non B-cells are reanalysed 
at 20 mmol/L glucose and only 10-15% increases their NADPH fluores-
cence intensity two to four fold. Sorting of the population with 
unchanged NADPH content yields virtually pure A-cells (Pipeleers 
et_ a]_. , 1985). 
Functional organization of islet cells: 
Functional analysis of the purified islet cells indicate 
that adult pancreatic B-cells are sociologically organized at three 
different levels. A first level is expressed in the coexistence 
of functionally diverse subpopulations, a second level is associated 
to the aggregated state of the cells and a third level is achieved 
by the synergistic interactions of the B-cells with their environ-
mental signals (Table 1). 
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Table l: The biosociology of pancreatic B-cells . 
Sociologic organisation Biological impact 
I. Coexistence of functionally Complementarity in 
diverse subpopulations functions 
1. Topography 
2. Hormone content 
3. Responsiveness to glucose 
4. Replicative activity 
II. Aggregated state of the Potentiation of cell 
cells response 
IIL Synergistic interaction Coordination in 
with environmental signals glucose homeostasis 
It has been accepted since a long time that B -cells are 
responsible for insulin production and release. A cells secrete 
glucagon (Hellman and Taljedal, 1972) and the D-cells secreting 
somatostatin, inhibit the secretion of insulin and glucagon (Alberti 
et al . . 1973; Chen el_ al_. , 1974). In the pancreatic is lets , the 
close topographical relationship of the somatostatin containing cells 
with and A-cells, evokes the possibil i ty of a local regulation 
of the release of insulin and glucagon by these cells . In ra ts . 
a proportion of B -cells are juxtaposed to the peripheral layer 
of islet non B-cells; the remaining B-cells form a central mass 
of homogeneous composition (Bencosme 8 Liepa, 1955; Lazarus Q 
7 
Fig. 1: (a) Electron micrograph of a B-cell X19.000 
(b) A nicrofilamnet (mf) between two rows 
of secretory granules X50.000 
(c) A nicrotubule (arrows) and microfilaments 
(asterisk) X37.000 
Orel et al . f1973) 
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Volk, 1962; Hellman, 1967; Orci, 1982). The peripherally located 
B-cells can be structurally and functionally coupled to islet non 
B-cells (Orci et. a h . 1973; Michael S Sheridan, 1981; Meda £t_ 
a l . , 1979) and exhibit in addition larger gap junctional area than 
B-cells in the centre of the islet (Meda e_t_ a]_. , 1980). Glucose 
and cyclic AMP rapidly increase the number of structurally coupled 
B-cells in the presence of extracellular calcium (Maes Q Pipeleers, 
1984). 
Insulin: 
Insulin was first recognized as a powerful stimulus to 
the permeation and utilization of glucose by various sensitive tissues 
(Levine and Goldstein, 1955). In addition to its antidiabetic or 
hypoglycemic action, the hormone also strongly influences the bio-
synthesis as well as the breakdown of major foodstuffs i . e . carbo-
hydrates, proteins and lipids (Krahl, 1961; Steiner, 1966; Fritz, 
1972; Steiner 8 Freinkel, 1972). The main targets of insulin action 
are l iver, muscle and adipose tissue . In l iver , which is insulin's 
major target tissue, insulin decreases glycogenolysis, gluconeo-
genesis and ketogenesis and increases glycogen and fatty acid syn-
thesis . Insulin induced changes in the metabolic patterns in l iver , 
muscle and adipose tissues appear to be due to alterations in the 
activities of the certain key rate limiting enzymes and transport 
system, as outlined in Table. 3-4. 
9 
HUMAN PROINSULIN 
t CMAJN 
•C PtPTlDl • 
Fig.2: Structure of human proinsulin showing sites of 
cleavage (dotted circles) by Trypsin. 
Kemmler ct al . (1972) 
10 
Table i : Insulin-glycogen old testament chronology. 
Year Authors 
Glycogen begat blood glucose 
Insulin begat glycogen synthesis 
Glycogen synthesis begat glycogen 
synthase 
Insulin begat glycogen synthase 
activation 
1987 Bernard C 
1922 Banting et al 
1957 Leloir et al. 
1960 Villar-Palasi Q 
Lamer 
Insulin begat covalent control 
of glycogen synthase by 
covalent phosphorylation 
Insulin begat cAMP-kinase 
Insulin mediated cAMP-kinase 
inactivation begat insulin 
mediator 
1963 Friedman S 
Larnor 
1967 Villar-Palasi a 
Wenger 
1974 Lamer et al . 
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Table j : Enzymes regulated by insulin and insulin mediator 
cAMP-dependent protein kinase 
Na+K+ ATPase 
I 
Pyruvate dehydrogenase phosphatase * 
(mitochondrial) 
T 
Glycogen synthase phosphatase T 
Adenylate cyclase (cell membrane) 
Low-Krn phosphodiesterase 
Acetyl-CoA carboxylase <^ 
Ca+ 2Mg+ 2 ATPase t 
Glucose-6-phosphatase I 
I 
Cheng 6 Lamer (1985) 
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Table 4 : Cellular events regulated by insulin and insulin mediator 
Lipogenesis 
Antilipolysis 
Down regulation of insulin 
Pyruvate dehydrogenase 
cAMP concentration 
Glycogen synthase 
Cheng 6 Lamer (1985) and Jarret t et al . (1985) 
receptor 
t 
t 
t 
t 
t 
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The possibility that insulin acts by binding to its target 
tissues was first suggested by Stadic e\_ aj_. (1953) on the basis 
of the uptake of iodoinsulin by isolated rat hemidiaphragms in 
vi tro. Antoniades and Gershoff (1966) and Crofford (1968) demons-
trated insulin uptake by isolated fat cells and attributed this 
rapid reaction to an association of the hormone with the plasma 
membrane. Binding of iodoinsulin to receptors in the plasma mem-
branes of its target cells has been directly demonstrated (House, 
1971; Kono and Braham, 1971). The correspondence between the 
relative biological potencies of various insulin analogues and their 
relative abili t ies to compete with iodoinsulin for receptor binding 
(Freychet ej_ a]_. , 1974; Gammelt'ift and Glieman, 1973; Simon e_t_ 
al. , 1974), suggests that the association between the insulin and 
its receptors is the physiologically significant one. 
Insulin action in the target tissues is primarily and essenti-
ally dependent upon the binding of the hormone to specific cell 
membrane receptors (Freychet, 1977) and probably to the intra-
cellular binding sites too (Hovart e_t_ al_. , 1975; Goldfine G Smith, 
1976). The resultant hormone receptor interaction initiates specific 
intracellular events such as inhibition of cAMP-dependent protein-
kinase, activation of phosphoprotein phosphatase and dephosphoryla-
tion of mitochondrial pyruvate dehydrgenase (Lamer and Villar-
Palasi, 1971; Lamer e_t_ ah , 1978; Lawrence and Larner. 1978; 
Oron et_ al_. , 1979). It was suggested that a 1200-1500 dalton hypo-
thetical peptide of the target cells may translate the hormone 
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receptor interactions into the intracellular molecular event (Lamer 
et a\_. , 1980). The identity and mode of action of this translator 
is not known. 
Structurally coupled B -cells coordinate and hence amplify-
their secretory activity via an intercytoplasmic exchange of signal 
molecules (Meda et a\_. , 1983, 1984), but direct evidence for such 
regulatory mechanism is still lacking. The higher insulin releasing 
action of glucose in structurally coupled B-cells could not be a t t r i -
buted to an increased rate of signal production as judged by the 
rate of glucose transport and oxidation (Gorus et_ a\_. , 1984) or 
of cyclic AMP formation (Schuit 8 Pipeleers, 1985). It is , however, 
conceivable that the aggregated state of the cells confer an intra-
cellular organisation which facilitates the process of hormone trans-
port and release (Pipeleers e_f a^. , 1976). Gap junctions have 
been recognised between reaggrt.gated B-cel ls (Pipeleers, 1985), 
with a number of junctional units which increases with the cellular 
cyclic AMP levels (int Veld ej_ a\_., 1985) and a configuration which 
rapidly varies with the extracellular glucose and calcium concent-
rations ( in ' t Veld e_t_ al_., 1986). The cellular structures implicated 
in the communication between B-cells are regulated by calcium, 
glucose and cyclic AMP certainly strengthens the hypothesis that 
intercellular interactions between adjacent B -cells may play a role 
in the potentiation of individual cell responses. 
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INSULIN BIOSYNTHESIS 
Insulin is synthesized initially as the preproinsulin at the 
rough endoplasmic reticulum (RER) of beta cell (Patzelt et_ aL . 
1978) and it comprises the major biosynthetic product in the micro-
somal fraction (Sorensen e\_ aL , 1970). Variety of secreted proteins 
are synthesized initially with amino terminal extention of 20-30 
amino acid residues (Milstein et_ aL , 1972; Kemper ejt_ aL , 1974; 
Boime et_ aL , 1975). These extensions appear to serve as the 
"Signal regions" for the binding of polyribosomes to the rough 
endoplasmic reticulum leading to vectorial discharge of newly formed 
peptides into the cisternae of endoplasmic reticulum (Blobol and 
Sabatine. 1971). These extensions normally are rapidly cleared 
away in the microsomes but are retained when appropriate mRNA 
fractions are translated in various cell free systems j_n vitro. 
The molecular weight of the bovine and rat preproinsulin is approxi-
mately 11,500-12,000. Preproinsulin have 23 additional amino acids 
at the amino terminus (Chan ejt_ a_l_. , 1976). These preproinsulins 
appear to be converted to proinsulin so rapidly under normal condi-
tions that they escape detection (Lernmark et_ a L , 1976). A dis-
tinctive feature of the process of insulin biosynthesis is the intra-
cellular proteolytic conversion of precursor to the hormone prior 
to its storage and secretion from the beta cells (Steiner, 1967, 
1978). Preproinsulin is converted to proinsulin by the removal 
of pre signal sequence in the cavities of RER. The molecule is 
then transferred to the Golgi apparatus via vesicles of RER (C)rci, 
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1974; 1982, 1985) by an energy requiring mechanism (Sharp e_t_ 
al . , 1975). The Golgi complex is involved in the initiation of 
proteolytic maturation of proinsulin to insulin (Orci, 1974; Steiner 
et a l . , 1970; 1974, 1976). Using electron microscope autoradio-
graphy, Orci (1986b) was able to show that trans Golgi cistcrnae 
and secretory granules of B -cells in their initial stage are coated 
with a protein named clathrin. Experimental evidences suggest 
that the coated granules play a crit ical role in the conversion 
of proinsulin to insulin and maturation of proinsulin. 
CONVERSION OF PROINSULIN TO INSULIN 
The mechanism of formation of biologically active insulin 
from proinsulin within the B -cells is not clear. This complex 
process requires a selective proteolysis of proinsulin (Orci 
1986a ). Conversion of proinsulin to insulin begins with the 
initial cleavage of the connecting segment at either its N or C-
terminal to produce the two chain intermediates with the molecular 
weight approximately that of proinsulin (Tung 8 Yip, 1969). Pro-
insulin is converted to insulin by excision of Arg sequence at 
positions 31, 32 and the Lys Arg sequence at positions 64, 65 
in the molecule. Conversion appears to involove initial attack 
by endoproteases on the C-terminal side of these dibasic sequences 
followed by the action of an exrpeptidase specific for C-terminal 
basic amino acids to remove sequentially the exposed basic residues 
(Docherty et_ al_. . 1982). Assays for the processing activity in 
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subce l lu la r fractions p repa red from insulinoma t issue have demons-
t ra ted that the sec re to ry gran .le compartment is a major in t ra -
ce l lu la r s i t e of concentration of the converting enzymes (Davidson 
et a l . , 1987a). Reaction products include both insulin and the 
in termedia tes des 31, 32 proinsul in and 64, 65 proinsul in which 
are formed by cleavage at one or o ther of the bas ic s i t e s followed 
by ca rboxypep t ida se H action. These in te rmedia tes are also p ro -
duced in intact B -ce l l s and correspond to the major c i rcula t ing 
forms of proinsul in immunoreactivity (Given et_ a\_. , 1985). At 
least th ree different ca ta ly t i c a c t i v i t i e s are involved in the con-
vers ion p roces s . These are designated type I endopep t idase , type 
II endopept idase and ca rboxypep t ida se H (Davidson e_t_ aj_. , 1987b, 
1988). One endopept idase ( type I) c leaves exc lus ive ly after the 
Arg 31, Arg 32 sequence at the B-C chain junction, the o ther ( typo 
II) c leaves p re fe ren t i a l ly after the Lys 64, Arg 65 sequence at 
the A-C chain junction, though it also a t t acks the B-C chain junct-
ion at around a tenth to a fifth of the r a t e . Ca rboxypep t idase 
H works equal ly well with s u b s t r a t e s extended C-terminal ly by 
Lys or Arg res idues a lbe i t at different r a t e s (Davidson et_ a l . , 
1987b). The pH optimum of al l the enzymes is 5.5 and thus c o r r e s -
ponds to the pH of the mature s ec re to ry granule (Hutton, 1982). 
The pH prof i les in each case are s h a r p suggesting that modulation 
in in t ragranular pH in the range of 4-7 could p rov ide a means 
of regualting the i r a c t i v i t i e s . There is sub t le difference between 
the two endopep t idases , type I a c t i v i t y (Arg Arg speci f ic) is 
v i r tua l ly abol ished at pH 7, the type II enzyme (Lys Arg p re fe r r ed ) 
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re ta ins about 30% of i t s a c t i v i t y . The c a r b o x y p e p t i d a s e enzyme 
is markedly reduced at neutral pH, however , even at 5q0 ol i ts 
maximal a c t i v i t y , it s t i l l vas t ly exceeds the maximal ra te of endo-
pro teo ly t ic c leavage. 
The enzymes involved in proinsul in processing r e q u i r e metal 
ions for a c t i v i t y . The ca rboxypep t ida se is a c lass ic Zn metal lo-
enzyme, while the endopept idases are ac t iva ted by Ca. Again 
there are differences between the endopept idase s u b t y p e s ; the 
type I r equ i re Ca in the mill imolar range for half maximal 
ac t iva t ion , the type II a 25-fold lower concentrat ion. The free 
Ca content of sec re to ry granules is p robab ly in the mill imolar 
range and would thus suppor t maximal ac t i v i t y (Mutton c_t_ a l . , 
1983). However, in the compartments through which proinsul in 
passes p r io r to reaching the granule, the overa l l content of Ca 
is lower and more Ca will be in a complexed form due to the 
more a lka l ine pH of the compartments . This dual control exer ted 
by Ca and pll ensures that final conversion of the single chain 
p recursor does not occur until it r eaches the granule compartment. 
This is important , since insulin is cons iderab ly less soluble than 
proinsul in (Grant e_t_ ah , 1972). 
The d i rec t ident if icat ion of the in t r ace l lu la r s i t e whore 
proinsul in is p ro teo ly t i ca l ly processed into insulin has been achieved 
by immunocytochemistry using a proinsul in speci f ic monoclonal ant i -
body (Urci , 1986a). Insulin immunoreact ivi ty is absent from the 
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Golgi stack of the pancreatic B-cells and first becomes detectable 
in clathrin coated secretory vesicles (Orci, 1986b), released from 
the trans Golgi pole, clathrin coated secretory vesicles transform 
into mature non coated secretary granules which contain the highest 
concentration of insulin immunoreactive s i tes . Maturation of clathrin 
coated secretory vesicles is accompanied by a progressive acidi-
fication of vesicular millieu, as evidenced by a cytochemical probe 
that accumulates in acidic compartments where upon it can be re-
vealed by immunocytochemistry (Orci, 1986a). Thus packaging 
of prohormone by energy dependent process into secretory vesicles 
and acidification of this compartment are critical steps in the 
proper proteolytic maturation of insulin. Once proteolysis of pro-
insulin begins in intact cells, the reaction becomes independent 
of energy exchange (Steiner, 1967). 
Pulse chase experiment in the presence of monensin showed 
that radioactivity was accumulated in the clathrin coated secretory 
granules, whereas mature non coated secretory granules showed 
a lower level of radioactivity as compared to control. Moreover, 
47% decrease in the radioactive insulin was observed at the end 
of 85 minute chase period under monensin treatment (Orci e\_ a_L , 
1984a). Replacement of Lysine and Arginine by their respective 
analogue (Canavine and Thialysine) resulted into strongly labelled 
clathrin-coated granules and weakly labelled non coated granules. 
Moreover, only 11% of radioactive products was detected as insulin, 
as compared to 78% in controls (Orci et a l . , 1984b). These obser-
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vations indicate the impairment of proinsulin conversion and accu-
mulation of radioactive secretory products in a clathrin coated 
Golgi related compartment of B-ce l l . Hence, conversion of pro-
insulin is linked to its unpurturbed passage through clathrin coated 
compartment and subsequent maturation of later into non coated 
secretory granules. 
THE INSULIN STORAGE GRANULE 
The B-granule is the primary storage site of the finished 
insulin (Grodsky, 1970) and a direct correlation has been established 
between the degree of granulation and the insulin content. Morpholo-
gical studies (Orci, 1986b) show that the insulin granule buds 
off from specialized regions of the trans Golgi network which are 
characterized by the partial coating of the cytosolic surface of 
the adjacent membrane with clathrin like proteins and the presence 
within the lumen of condensing secretory material. Subsequent 
maturation involves further condensation of the matrix consituents, 
reduction in granule diameter and the dissociation of the coat pro-
teins. The fact that granule surface area decreases during maturat-
ion suggests that membrane lipid is being removed, presumably 
by a microvesicle mediated process. 
The ion composition of such granules differs markedly from 
the cell as a whole and from the surrounding cytoplasm (Hutton 
et al . , 1983). 
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An apparent increase in granule Ca content that is observed 
following glucose stimulation of islets (Herman e_t_ aL , 1973; Howell 
et_ a_L, 1975) suggests that the organelle may have modulatory effects 
on cytosolic free Ca concentrations. How Ca and inorganic ions 
get into the granule interior, however, is presently unknown. Around 
80% of the protein in the granule is accounted for as insulin and 
C-peptide, a further 10% appears to be in the granule core and 
i ts surrounding mantle and a further 10% in the membrane (Hutton 
6 Peshavaria, 1982). 
In quantitative terms, the major protein component of the 
beta granule, apart from insulin, is the detached C-peptide which 
is present in equimolar amounts with insulin but it is unclear to 
what extent its presence affects the crystallization process (Howell, 
1984). The size of individual storage granule (0.2-0.3 pM) is very 
small but enough to store very- large numbers of granules-13,000 
in each B -cell (Dean, 1973). The question as to whether the beta 
granule merely plays a passive role as a storage container for insulin 
or whether the granule itself plays an active part in its own exten-
sion, remains to be resolved (Orci 6 Malaisse, 1980; Yaseen et_ 
al_. , 1983; Hutton 8 Peshawaria, 1982). 
Evidence for the presence of a proton-translocating ATPase 
in the insulin secretory granule has come from studies of the ATPase 
activity in freshly isolated osmotically intact insulin granules com-
bined with determination of the pH-gradient across the secretory 
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granule membrane, measured by the space of distribution of a radio-
labelled permeant base, methylamine, and the transmembrane voltage 
difference, determined from the distribution of a radiolabeled anion, 
thiocyanate (Hutton 5 Peshavaria, 1982; Hutton, 1982; Hutton e^ 
al . , 1983). The results of such experiments are readily interpreted 
within a chemiosmotic model which postulates f i rs t ly, that there 
is a catalytic activity in the membrane which transports hydrogen 
ions vectorially from the cytosol into the granule interior at the 
expense of ATP hydrolysis , and secondly that the passive conducti-
vity of the membrane to protons is low. ATP hydrolysis generates 
a pH gradient of around 1-1.5 units and establishes a voltage potential 
across the membrane of around 45 mV, positive inside. In terms 
of its substrate specificity, ionic requirement and inhibitor profile, 
the insulin granule proton pump is similar to the multimeric protein 
isolated from chromaffin granules of adrenal medullary cells , to 
proton translocasas found in elements of endocytic pathway and indeed 
to similar enzymic activities found in intracellular vesicles in d is-
tantly related organisms (Al-Awaqati, 1986; Hellman et^  al_. , 1986). 
INTRACELLULAR TRANSPORT OF INSULIN 
Insulin along with equimolar concentration of C-peptide 
is released into the extracellular space from the secretory granule 
by exocytosis or emiocytosis (Orci, 1974; Lacy, 1975; Cerasi, 1975). 
Before the release the storage/secretory granule are transported 
to the cell membrane by a system of contractile action like micro-
tubules (Lacy e_^  <il_., 1968; Malaisse et a l . , 1972; Pipeleers et 
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a l . , 1976). The secretory granules subsequently lie close to the 
cell membrane, a feature commonly called 'lining up' or margination 
and the granule sac soon fuses with the cell membrane and opens 
up to release the granule content into the extracellular space. While 
the fusion of the granule sac with the cell membrane is supposed 
to be under the control of microfialmentous cell web (Orci et_ a l . , 
1972), the fission of the fused membranes apparently is mediated, 
as demonstrated by certain 'Chemi Osmotic' changes (Hermans fi 
Henquin, 1986). The conformation and contraction of microtubular 
microfilamentous system as well as other secretion related cellular 
phenomena are apparently modulated by intracellular and trans-
membrane fluxes of Ca (Flatt et_ a h , 1980). After the release of 
their contents the empty membrane sacs of secretory granules become 
pinched off into the cytoplasm as pinocytotic microvesicles. These 
vesicles are either returned to the Golgi complex or fused with 
lysosomes (Meda, 1978) and becomes degraded (Lacy, 1975). 
Although morphological evidences amply demonstrate emio-
cytosis as the major mode of insulin release, it was, however, 
found insufficient to explain certain quantitative and qualitative 
aspects of insulin release, even in basal conditions. An alternative 
mode of insulin release such as intracellular dissolution of granules 
in the hyaloplasm and the subsequent diffusion of insulin into the 
extracellular space has been suggested by Fukuma (1974). Studies 
on islets and insulinomas suggest that the free cytosolic Ca concent-
ration is the major intracellular signal that triggers exocytosis. 
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Untill r ecen t ly , the evidence to suppor t th i s view was inferred 
45 from e i the r Ca flux s tud ies (Malaisse-Lagae 8 Malaisse, 1971) 
or ex t r ace l l u l a r Ca requirement for insulin re lease (Wollheim et 
a l . , 1981; Grodksy, 1966). In secretagogues of insulin where Ca 
appea r s to be the signal for re lease is high K+ concentrat ions that 
depo la r ize the plasma membrane openir.g voltage dependent Ca channels , 
allowing Ca to enter the B-cells (Wollheim 5 S h a r p , 1981; Grodsky 
8 Bennett, 1966; Wollehim 6 Jan j ic , 1984a; Wollheim 6 Pozzan, 1984b; 
Prentki 8 Wollheim, 1984). Now the ex t r ace l l u l a r Ca pool is involved 
and the iden t i ty of the in t r ace l lu la r signal for glucose s t imulated 
insulin r e l ease a re s t i l l unclear (Kikuchi 8 Wollheim, 1978; Malaisse 
et_ al_., 1978). 
INSULIN RECEPTOR 
Fi rs t s t ep in the action of insulin on the plasma membrane 
of the cel l is i t s binding to speci f ic r ecep to r s i t e s (Roth e£ aj_. , 
1975; Kahn et_ al_., 1981). The demonstration that the number of 
insulin recep to r s i t e s per cell was finite and r ecep to r s were on 
the outer surface of the cell and they were speci f ic for insulin 
was made poss ib ly in 1971, when Freychet et^  aL (1971)8 Cuatrecasas 
125 (1971) in t roduced insulin labe l led with 125 iodine ( I ) , which 
allowed the p rec i se charac te r i za t ion of the ligand r ecep to r in te rac t ion . 
Studies were c a r r i e d out at low temperature to minimize hormone 
degradat ion . The surface in teract ion of insulin with i t s r ecep to r 
was visual ized for the f i rs t time by Orci et a l . (1975) who detected 
in su l in -dex t r an - f e r r i t i n complexes spec i f ica l ly bound to hepatocyte 
125 
membranes p repa red by the freeze etching technique . When I 
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insulin was incubated with freshly isolated rat hepatocytes at 37°C, 
the autoradiographic reaction was not only present at the cell surface 
as expected, but was also detectable in the ce l l ' s interior (Carpentier 
el. a l . . 1977). 
Biochemical and morphological studies indicate that the 
insulin receptor is internalized following ligand binding (Fehlmann 
ert a L . 1982; Gordon et_ a L . 1982; Hedo 6 Simpson, 1984; Marshall 
et^  a]_., 1981). The induction of biological signal in the target cell 
upon ligand binding to its specific receptor requires transduction 
mechanism between the cell surface event and the cell cytoplasm. 
Nature of the insulin action mechanism have been obtained by the 
finding that the insulin receptor is a tyrosine specific protein kinase 
(Kasuga £t_ aL , 1982; 1983; Petruzelli et_ a h , 1984). The insulin 
receptor is composed of two external binding domains (A-subunits) 
and two transmembrane domains (B -subunits). All these subunits 
are linked by disulfide bonds. A current hypothesis of transduction 
is that insulin binding to the A-subunit stimulates autophosphorylation 
of tyrosine residues on the intracellular domain of the B -subunit 
which in turn triggers the activation of phosphotransferase (Rosen 
et_ aL , 1983; Yu et_ aL , 1984; Herrera 6 Rosen, 1986) and catalyses 
tyrosine phosphorylation of specific substrates . This hypothesis 
has gained support recently by the discovery of various substrates 
which undergo tyrosine phosphorylation during insulin binding (White 
et_ aL , 1985; Izumi et_ aL , 1987; Gibbs 8 Leinhard, 1986; Rees 
Jones 5 Taylor, 1985; Haring et a l . , 1987). Moreover, inhibition 
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or deletion of the insulin receptor tyrosine kinase blocks insulin 
action (Morgan et_ a h , 1986; McClain et_ a L , 1987; Chou e^ a h , 
1987). 
Monensin, inhibits receptor recycling, al ters the number 
of surface insulin receptors over short periods of time only if insulin 
is present in the incubation medium (Carpentier et a l . , 1984). 
This indicates that the insulin receptor is not turning over in the 
absence of the ligand. Similar conclusions were recently reached 
by Backer et_ a\_. (1989), who found an acceleration in the rate 
of insulin receptor internalization following the addition of insulin. 
Thus, endocytosis of the insulin receptor is induced by insulin 
binding. The mechanism by which insulin triggers endocytosis 
of its receptors, however, is unknown. It was initially suggested, 
on the basis of inhibition studies, that transglutaminases were in-
volved (Davies et_ aL , 1980). Recent studies confirmed that auto-
phosphorylation of the insulin receptor is not required for its inter-
nalization (Azakawa et_ aj_. , 1985; Backer et_ a_l_. , 1989; Triscitta 
et al. , 1989). Thus autophosphorylation of the insulin receptor 
does not seem to be the general mechanism for triggering insulin 
receptor internalization. 
THE ALPHA CELL AND ITS FUNCTION 
In the islets of man, rat and large number of animal species, 
alpha cells were identified by a variety of staining methods, of 
which the phosphotungstic acid-hematoxylin and si lver impregnation 
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(Grimelius, 1968) methods were most popular. However, these methods 
failed to elucidate the nature of alpha cell secretory product. 
Using immunofluorescent and immunohistochemical techniques, Baum 
et^  aL (1962), Okada et_ aL (1968) and Bussolati et^  ah (1971) pro-
vided the first definitive proof at the cellular level for the alpha 
cell origin of glucagon. At the electron microscope level, immuno-
staining was found restricted to the core of the alpha cell secretory 
granule which contains glucagon (Lange, 1973). 
Ultrastructurally, the alpha cells are identified by their 
characteristic highly electron dense secretory granules. The dense 
core of the granule, unlike that in the beta granule, is only rarely 
crystall ine, spherical in shape and is separated from the surrounding 
membrane sac by a relatively dense 'halo ' (Herman et_ al_., 1964). 
In most species including man, the alpha cells constitute 
20-30% of the total islet cells . Further, the proportion of the 
alpha cells to the rest of the cell types is relatively low in the 
head and body of the pancreas than in the tail portion (Orci et_ 
a l . . 1976). In size, the alpha cell is three times smaller than 
the beta cell (Hellman. 1959). 
Glucagon 
Long before the identification of glucagon in the A -cel ls , 
the hormone was partially isolated from an extract of bovine pancreas 
as a hyperglycemic substance, and was given the name 'glucagon' 
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in 1923 by Kimball and Murlin. Three decades later, Staub et 
al_. (1953, 1955) crystallized a pancreatic hyperglycemic-glycogenolytic 
factor (HGF) from pancreatic extracts and identified it as glucagon. 
Glucagon is a single chain polypeptide consisting of 29 
amino acids and has a molecular weight of 3485 daltons. The peptide 
contains the relatively rare amino acid, tryptophan. Porcine, bovine, 
human, rat and rabbit glucagons are identical in their primary 
structure (Moody and Sundby, 1980). 
Glucagon plays an important role in the homeostatic regulation 
of glucose, amino acid and lipid metabolism. Glucagon is a catabolic 
hormone and its actions are thus essentially opposite to those of 
insulin. Glucagon is thus one of the most potent insulin counter 
regultory hormones (Bolli at_ a\_., 1984) and has glycogenolytic 
(Sokal, 1970), gluconeogenic (Sokal, 1966) as well as lipolytic and 
ketogenic actions (Liljenquist et_ al_. , 1974). Among other effects, 
glucagon, when administered in large doses, stimulates growth hor-
mone release from pituitary and this effect has been used as a 
provocative test for evaluation of growth hormone secretion (Sawin 
a Mitchell. 1970). 
In the target tissues (which are largely common for both 
insulin and glucagon) glucagon brings about its effects by binding 
to specific glucagon receptors (lyenger and Herberg, 1984; Hagopian 
and Tager, 1984) and by activating adenylate cyclase (responsible 
for cAMP formation) (Allgayer et a l . , 1982). It has also been 
33 
shown that glucagon counter regulates insulin action in adipocytes 
by inhibiting insulin receptor activity and that this may be mediated 
by glucagon stimulated cAMP formation (Yamuchi and Hashizuma, 
1986). 
THE DELTA CELL AND ITS FUNCTION 
Numerically, the delta cell is the least abundant cell type 
and accounts for about 5-10% of the islet cell population (Orci, 
1977; Van Assche et^  a L , 1980). The delta cell produce a peptide 
hormone somatostatin which is a 1.6 K-dalton tetradecapeptide with 
a single intra-chain disulphide bridge (Patel et^  a L , 1981; Vinik 
et a l . , 1981). Somtatostatin is synthesized as preprosomatostatin 
(Horbart et^  £L , 1980; Goodman et_ a]_. , 1987) and released as somato-
s t a t i n s (S-28) or somatostatin-14 (S-14) (Pradayrol et_ al_. , 1980; 
Benoit et_ a l . , 1980; Patel et. a l . , 1981; Gluschankof e^ al_. , 1984). 
The relationship between the A1-cells and D-cells of Bloom 
(1931) is st i l l controversial. Hellerstorm and Hellman (1960) devised 
a si lver impregnation method for its demonstration in islet sections, 
called it as A.-cell . Munger et^  al_. (1965) confirmed the distinct 
identity of cell type and Fujita (1968) suggested an endocrine function 
to i t . Van Assche (1970) has pointed out that not all D-cells are 
stained by the Hellman-Hellerstorm silver technique and has ex-
pressed the opinion that the D-cells of Bloom (1931) constitute 
a heterogeneous groups of is le ts . Some of which st i l l await identi-
fication. 
34 
Using electron microscopic methodology the delta cell can 
be recognized by the low electron density of its secretory granules. 
The granules show a amorphous core around which the membrane 
sac is closely applied with l i t t le electron-lucent 'halo ' between 
the membrane and core (Goldsmith e£ £l_., 1975). The delta-cell 
is also distinguished by its cellular extensions which often protrude 
into the intercellular spaces between adjacent non delta cells 
(Goldsmith e\_ a L , 1975). 
The hormone somatostatin produced by delta cells decreases 
the rate of entry of nutrients from gut into circulation (Schusdziara 
et al_., 1979), alters hepatic gluo se output, regulates glucose dis-
posal to tissue and modulate the central nervous system actions 
on glucoregulation (Brown el_ a\_. , 1981). However, the mechanism 
by which somatostatin brings about these effects is not known. 
In the endocrine pancreas, addition of somatostatin lead to inhibi-
tion of insulin and glucagon release (Albertii et_ al_., 1973; Koerker 
et^  al_. . 1974; Mandarino et^  ah , 1981; Brown et_ aL . 1981). 
INSULIN AND GLUCAGON RELEASE FROM THE ISLETS OF LANGERHANS 
Homeostatic regulation of metabolic fuels involves intricate 
balance in the secretion of islet hormones. Potentially important 
regulatory factors include hormones, neurotransmitters, substrates, 
and intrinsic response of the l iver (Hepatic glucose autoregulation). 
Insulin suppresses glucose output by the l iver (both glyco-
genolysis and gluconeogenesis) and stimulates glucose uptake by 
35 
peripheral tissues. Therefore, unless other factor intervene, increase 
in insulin secretion lowers plasma glucose concentration. The major 
physiologic regulator of insulin secretion is plasma glucose. Increase 
in plasma glucose above normal level stimulates insulin secretion 
whereas, decrease in plasma glucose below a certain level, suppresses 
i t . With ingestion of a mixed meal, the absorbed amino acids 
and certain gut factors augment the insulin response to the post-
prandial increased plasma glucose. Normally at arterial plasma 
glucose concentrations ^.3 mM (50 mg/dl), insulin secretion is com-
pletely suppressed (De Feo et_ a h , 1986). Suppression of insulin 
secretion during hypoglycemia is important in permitting restoration 
of euglycemia, because glucose production is more sensitive to insulin 
than glucose utilization (Rizza £t_ al_. , 1986). 
Like insulin, glucagon secretion is primarily regulated by 
plasma glucose concentration. Increase in plasma glucose, suppresses 
glucagon secretion, whereas, decrease in plasma glucose stimulates 
i t . With the ingestion of mixed meal, the stimulatory effect of 
absorbed amino acids generally overcomes the suppressive effect 
of the hyperglycemia; so that circulating glucagon concentrations 
increase. Glucagon acts exclusively on the l iver , where it stimulates 
both glycogenolysis and gluconeogenesis and increases glucose output 
within minutes (Cherrington ei_ a]_. , 1981). Under certain conditions, 
glucagon concentration also stimulates hepatic production of ketone 
bodies, which during fasting or prolonged hypoglycemia may substi-
tute partially for glucose, in meeting the bra in ' s energy needs 
(Owen et al . , 1967). 
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Epinephrine secretion increases during hypoglycemia. It 
stimulates glucose production and limits glucose utilisation. Action 
of epinephrine is mediated through B-adrenergic mechanisms (Riz/a 
et_ ah , 1980). 
Growth hormone 
Cortisol and growth hormone secretion increase during hypo-
glycemia, these hormones antagonize the effects of insulin and thus 
limit both stimulation of glucose utilization and suppression of its 
production by insulin. These effects usually require several hours 
to occur (McGorman et_ a l . , 1981). There is evidence of synergistic 
interactions among glucagon, epinephrine, and Cortisol in their hyper-
glycemic effects (Eigler e_t_ aL , 1979). Growth hormone (GH) has 
an insulinotropic action on pancreatic B-cell, Elevation of growth 
hormone levels in vivo stimulates insulin production concomitantly 
with an increased B-cell replication and development of islet hyper-
plasia (Pierlussi et_ a L , 1980, Parson £t_ al_. , 1983). Hypophysectomy 
in the adult rat causes a decrease in insulin biosynthesis, a poor 
insulin secretory response to glucose and diminished islet insulin 
stores (Pierlussi et a l . . 1982). Studies on the stimulation of insulin 
production by GH have also indicated a direct effect of the hormone 
on B-cell (Pierlussi et_ al_. , 1982; Whittaker 8 Taylor, 1980). Growth 
hormone has a direct stimulatory effect on islet cell insulin biosyn-
thesis , release, glucose oxidation and general protein biosynthesis. 
However, its action on 13-cell replication is partly mediated by 
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paracrine release of somatomedin c/IGF-I (Swenne et a l . , 1987). 
Fatty acids 
Octanoate, valerate, butyrate and propionate (short chain 
fatty acids) , oleate and plamitate (long chain fatty ac ids) , B -hydroxy 
butyrate and actoacetate (Ketone bodies) stimulate insulin release 
from islets of various species in the presence of non stimulatory 
concentration of glucose (Hawkins et a l . , 1971). Palmitate is able 
to pontentiate dose dependency (0 to 1 mmole/L) glucose stimulation 
of 'de novo' phospholipid synthesis and insulin release (Vara et_ 
al_. , 1986). 
Amino acids 
L-Arginine (Palmer ei_ al_. , 1975), L-Leucine and L-phenyl-
alanine (Landgraft, 1974) have been shown to stimulate the release 
of insulin by different mechanisms. L-Arginine, the most potent 
amino acid for insulin release stimulates the release by directly 
eliciting glucagon from the alpha cell (Milner, 1970). Non metaboliz-
able analogs of Leucine and Arginine stimulate insulin secretion, 
which suggest that amino acids may trigger islet hormone secretion 
via membrane receptor (Effendic ej^  a l . , 1975). Arginine and Lysine 
(cationic amino acids) are released by the conversion of proinsulin 
to insulin (Steiner et_ aj_. , 1980). Arginine has been reported to 
inhibit the formation of proinsulin (Schatz et a l . , 1975) as well 
as that of glucagon (Hellerstrom et al . , 1972). The proteolytic 
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conversion steps in hormonal precursor processing are not influenced 
by cationic amino acid as studied in intact islets and in a cell 
free translational system. It is concluded that Arg and Lys inhibit 
protein synthesis in islet cells at the translational level. The 
release of these amino acids by prohormone conversion may exert 
a feedback control on proinsulin iurmation that is modulated by 
glucose (Patzelt, 1988). 
CAMP 
cAMP has been shown to have a marked potentiating effect 
on the abili ty of glucose to stimulate insulin release from is lets . 
In addition, intracellular concentrations of cAMP can be modestly 
increased by stimulatory concentrations of glucose (Charles e_t_ al . , 
1973; Grill 5 Cerasi, 1974; Capito 8 Hedeskov, 1974). However, 
the mechanism by which glucose affects the cAMP content in islets 
is not known. 
There are conflicting reports about the level of cAMP in 
B-cells during glucose stimulated insulin release. cAMP levels 
have been reported to be unchanged (Kipnis, 197U; Montague et_ 
al. , 1971) or increased (Charles et_ al_. , 1973; Hellman e_t^  al_. , 1974; 
Grill 8 Cerasi, 1974; Rabinovitch _et_ aj_. , 1978; Bouman et_ a]_. , 1979; 
Malaisse e_t_ al_. , 1984). However, despite these discrepancies, 
glucose clearly elicits the most consistent increase in cAMP content 
of isolated islets when degradation of the nucleotide is inhibited 
by the addition of methylxanthines (IBMX) (Malaisse et al . , 1984; 
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Rabinovitch et_ aL , 1978). It is clear that increasing the cAMP 
content of islets (by addition of dibutyryl cAMP, methylxanthines, 
forskolin, or glucagon) potentiates glucose stimulated insulin secretion 
(Malaisse £t_ al_. , 1984; Rabinovitch et_ al_., 1978; Brisson et_ a l . , 
1972; Wieden Keller et_ aL , 1983; Henquin 8 Meissner, 1984; Steinberg 
et a l . , 1984) and the potentiation increases with the glucose concent-
ration. 
Some evidences suggest that the raised intracellular Ca 
concentration in response to glucose is responsible for stimulation 
of adenylate cyclase. It has been shown that the effect of glucose 
on increasing cAMP depends on the presence of extracellular Ca 
(Charles et a L , 1975; Hellman, 1976). Ca-calmodulin has been 
shown to stimulate rat adenylate cyclase activity (Valverde ej_ a_L , 
1979; Sharp el_ a\_., 1980). However, since Ca-calmodulin fails to 
affect mouse islet adenylate cyclase (Thams £t_ jiK , 1982), Ca-cal-
modulin activation of adenylate cyclase does not seem to be a plausi-
ble mechanism for glucose stimulation of adenylate cyclase. 
It has been demonstrated that isolated B-cells exhibit a 
markedly lower cAMP formation than do B-cells in intact is le ts , 
glucose alone does not influence cAMP concentration in purified 
B-cells, but enhances glucagon induced cAMP formation in these 
cells, suggesting that this lack of glucose stimulation may be caused 
by separation of B-cells from glucagon containing A-cells (Schmit 
8 Pipeleers, 1985). Similarly, somatostatin produced in D-cells 
41 
which inhibits cAMP accumulation in iselts (Bent-Hansen et a l . , 
1979) may be involved in the paracrine regulation of B-cell function. 
Protein kinase C-dependent protein phosphorylation has been identified 
in pancreatic islets (Lord 6 Ashcroft, 1984; Thams et^ a L , 1984) 
and glucose has been found to induce protein kinase-C mediated 
protein phosphorylation, in neonatal islets (Dunlop 6 Larkins, 1986). 
It appears, therefore, that glucose stimulates islet adenylate cyclase 
by activation of protein kinase-C and thereby potentiates the effect 
of endogenous glucagon on adenylate cyclase (Thams et^  al_., 1988). 
Glucose 
The mechanism by which glucose induces insulin release 
from B-cell is poorly understood. However, evidences indicate 
that glucose induces insulin release via a direct interaction with 
an, as yet, hypothetical 'glucoreceptor' of B-cell ("regulator site" 
model; Fajans e\_ a h , 1971; Ashcroft, 1980) or via the metabolism 
of glucose in the B-cells ("Substrate si te" model; Coore and Handle, 
1964a,b; Matschinsky and Ellerman, 1973; Malaisse e_t_ jil_. , 1982). 
Although the controversy regarding the sufficiency of these 
models to explain the mode of glucose induced insulin release is 
sti l l continuing, valuable informations have been generated during 
the course of the studies on metabolic make up of B-cells and its 
implication in the Q -cell function. Glycolysis, pentose phosphate 
shunt, sorbitol pathway, Kreb's cycle, adenosine triphosphate (ATP) 
generation and utilization of redox systems etc. have all been identi-
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fied and studied in B-cells (Matschinsky, 1972; Lange, 1973; Verspohl 
et_ al_. , 1979; Malaisse et_ al_. , 1982). 
The relationship between the extracellular glucose concent-
ration and the rate of insulin release is signmoidal. As illustrated 
(Fig. 9 ), glucose concentration below approximately 3 mM do not 
influence the secretory rate. The threshold concentration is 4 
mM. The largest increase in insulin secretion occurs between 4 
and 17 mM of glucose, which means that the B-cells are acutely 
sensitive to small changes in the glucose concentration within the 
physiological range. At s t i l l higher glucose concentration, the 
curve tends to reach a plateau. Half maximal secretion rates required 
8 mM glucose in mouse and 6 mM in rat (Ashcroft et a l . , 1972). 
Grodksy et^  a\_. (1968) first demonstrated the biphasic insulin 
secretion in response to sudden increase in glucose concentration 
("Square wave pulse" of glucose). An increased glucose concent-
ration elicits a latency period, which returns more or less to 
the basal level within 5-10 minutes. This first phase is followed 
by a second prolonged phase with a more gradual increase in the 
rate of insulin release (F ig . io ). A two compartment model has 
been proposed to explain this biphasic response (Grodsky et a l . , 
1969). According to this model a small compartment of insulin 
is particularly labile to glucose and other stimulants and the first 
rapid phase of secretion is because of emptying of this compartment. 
The large compartment containing stored insulin is relatively stable, 
provides the small compartment with insulin is relatively stable, 
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Table 5: Effect of carbohydrates and their derivatives on release 
of insulin by mouse is le ts . 
Initiators 
Glucose 
Mannose 
N-acetyl-
glucosamine 
Inosine 
Glyceraldehyde 
Dihydroxyactone 
Glucosamine 
Potentiators 
Fructose 
N-acetylglucosamine 
Sorbitol" 
L-Glyceraldehyde 
Mannoheptulose 
Glucsamine 
Pyruvate 
Inhibitors 
Mannoheptulose 
Glucosamine 
No effect 
L-Glucose 
2-Deoxy-
glucose 
Galactose 
3-O-methyl-
glucose 
Gold 
thioglucose 
Ribose 
Ribitol 
Xylitol 
Unless otherwise stated all carbohydrates are the D-stereoisomer. 
Rat islets 
Compiled from data of Ashcroft ei_ <J_. (1972, 1973), 
Capito and Hedeskov (1976), Malaisse et_ ah (1974) and 
Williams 8 Ashcroft (1978). 
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also release insulin directly but at a much slower rate than the 
small compartment. This model was further extended by kinetic 
studies (Grodsky, 1972a.b). The mechanism of glucose induced 
insulin secretion has been reviewed by Hedeskov (1980). 
NEURAL INFLUENCES 
Insulin secretion can be directly influenced by the central 
nervous system. Sympathetic and parasympathetic nervous systems 
have been implicated as modulators of alpha and beta cell of islets 
of Langerhans (Woods and Porte, 1974). Some hormonal peptides 
such as gut hormones, gastrin and cholecystokinin play important 
roles as neuroregulators. Cholecystokinin is a brain and gut peptide 
discovered by Ivy and Oldberg in 1928. It was isolated and charac-
terized by Jorpes and Mutt in 1968. They are located in central 
nervous system (Dockray, 1976; Larsson and Rehfeld, 1977; Mueller 
et_ aL , 1977; Rehfeld el_ aL , 1978a,b; Larsson and Rehfeld, 1979) 
and synthesized in neuronal tissue (Golterman et_ a L , 1980). Chole-
cystokinin is one of the gastrointestinal hormones capable of stimu-
lating insulin secretion (linger et^  aL , 1967; Buchnan ei_ a\_., 1968; 
Dupre ert a\_., 1969; Ahren 8 Lundquist, 1981; Szecowka et_ aL , 
1982; Okabayashi et^  aL , 1983; Verspohl et^  aL , 1986a). Contrary 
to these-observations, some workers have suggested that the insulin-
otropic effect previously attributed to CCK may be due to contami-
nating gastric inhibitory polypeptide (GIP), present in crude pre-
parations of CCK, and not to CCK itself (Rabinovitch 8 Dupre, 
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Fig. 11: The amino acid sequences of porcine cholecystokinin 
(CCK-39) (left) and gastrin ( r ight ) . 
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1972; Dupre et_ aj_. , 1973; Rabinovitch 8 Dupre, 1974). However, 
pure preparations of natural porcine CCK (Otsuki ei_ a L , 1979a), 
synthetic COOH-terminal of octapeptide of CCK (CCK-OP) (Frame 
et a_L , 1975; Williams 8 Champage, 1979; Fujimoto 8 Champage, 
1979) and synthetic caerulein, which contains a COOH-terminal penta-
peptide identical to CCK (Otsuki et_ a L , 1979b; Bertaccini, 1970; 
Ohneda et a l . , 1978) have also been shown to stimulate insulin 
and glucagon secretion both _iri vivo and _in vi t ro . Specific CCK 
receptors (Bmax = 8.1 pmole/mg protein; Kd=2.3 ± 0.4 mM) have 
been demonstrated in rat pancreatic islets (Verspohl et_ a L , 1986a). 
Alteration in insulin secretion can occur in spontaneous hyper and 
hypothyroidism (Renould et_ a_L , 1974). 
Changes in insulin secretion can also occur during preg-
nancy (Saudek e± aL , 1975) the estrous cycle (Bailey and Matty, 
1972) and after the administration of oral contraceptives (Spellacy 
et aL , 1972). Progesterone administration elevates basal insulin 
level and insulin response to glucose (Kalkhoff e_t_ al_., 1970). 
Estrogen (Spellacy et_ aL , 1972) and testosterone (Bailey and Matty, 
1972) does not affect islet function. 
Glucocorticoids have no effect on _in vitro islet cell function 
but prolonged exposure to these are concentrated in synaptic vesicles 
from where they are released like other neurotransmitters (Fmson 
et a l . , 1980). CCK-nerve terminals are present in pancreatic islets 
(Larsson and Rehfeld, 1979). It seems that C-terminal tetrapeptide 
amide Trp-Met-Asp-Phe-NIL is predominant form of CCK in these 
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nerves. It is referred to as CCK-4 and is common to both CCK 
and gastrin. Hehfcld (1971), Ahmad et_ ah (1984) and Khalid 
et al . (1986) studied the effect of various cholecystokinins and 
gastrin and found that CCK-4 was more effective in releasing insulin 
in man and in mammals (Rehfeld et al . , 1980). Larsson 8 Rehfeld 
(1977) further observed that the tetrapeptide amide has a common 
evolutionary origin. Biologic activity of this peptide resides on 
the C-terminal tetrapeptide sequence and the remaining part of 
the peptides modify their potency on various target t issues. Study-
ing the effect of different forms of CCK on insulin release, Rehfeld 
et aJL (1980) have found that all of them stimulate the secretion 
of pancreatic hormones and that the CCK-4 is the most effective 
one. It is effective even at the dilution of 10" M. The intact 
tetrapeptide amide with free Trp and -Phe-NH„ terminii seems 
necessary for biologic activity. 
In more recent studies, cholecystokinin has been shown 
to augment the insulin response to hyperglycemia in rats (Sakamoto 
et_ al_. , 1982; Zawalich at_ aL , 1986; Rosseti et_ al_.. 1987) and dogs 
(Hermansen, 1984) but not in pigs (Lindkaer £t_ al_. , 1981). In 
rat pancreatic i s le ts , specific CCK binding sites have been demons-
trated (Sakamoto e_t^  al_., 1985; Verspohl et^  a_l_. , 1986a), whether 
cholecystokinin which is released after ingestion of amino acid 
and fat containing meals may act as insulinotropic hormone in man 
is not clear (Liddle et a l . , 1985; Owyang et a l . , 1986). 
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SULPHONYLUREAS 
The blood glucose lowering effects of sulfonylureas have 
been attributed to their ability to stimulate the release of insulin 
(Grodsky et_ a\_. , 1967; Pfieffer et_ aj_. , 1984) and to potentiate 
its biological actions (Feinglos fi Lebovitz, 1978; Lebovitz, 1984). 
The compounds are widely used in the treatment of NIDDM (Gerich, 
1985) in which a deficiency in insulin release and or insulin recog-
nition appears responsible for hyperglycemic state (Reaven, 1984). 
Their therapeutic value i s , however, limited by insufficient know-
ledge concerning the primary defects to be treated as well as con-
cerning their pancreatic and extrapancreatic effects in chronically 
treated patients, sulfonylureas has been found to provoke a rapid 
discharge of insulin as a result of ionic fluxes that occur after 
their binding to the plasma membrane (Malaisse e\_ a\_. , 1983; Gylfe 
et a l . , 1984). it is unknown whether this effect is related to 
the synergistic regulation by nutrient and (neuro)hormonal compounds 
- (P ipe leers et_ a l . , 1985a). Furthermore, it is controversial whether 
the sulfonylurea induced secretion also occurs under conditions 
of maximal glucose stimulation (Cerasi 8 Kaiser, 1983; Metz et_ 
a l . , 1982; Kadowski e_t^  ah , 1983). Little information is available 
on the long term effects of sulfonylureas, i . e . on insulin synthesis 
and secretion (Feinglos 6 Lebovitz, 1978). Increase in plasma 
insulin concentration, disappear in many cases during chronic sulfo-
nylurea therapy. The enhancement of insulin sensitivity is usually 
maintained and may be the major mechanism by which sulfonylureas 
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exert their long term hypoglycemic effects. Both the liver and 
extrapancreatic peripheral tissues (muscle and adipose tissue) may 
be involved in this enhancement of insulin action (De Fronzo S 
Simonson, 1984; Mc Caleb e_t_ ah , 1984). 
Several investigators have pointed to the enhanced glucose 
removal as the major contributor to the hypoglycemic effects of 
sulfonylureas. Putnam e\_ a\_. (1981) demonstrated that chronic glipi-
zide treatment potentiate insulin mediated glucose uptake in dogs. 
Maloff and Lockwood (1981) have shown that sulfonylureas increases 
glucose transport in adipocytes. In the perfused rat hindlimb, 
tolbutamide enhances insulin stimulated glucose uptake (Daniels 
6 Lewis 1982). 
Other investigators have concluded that a major component 
of the sulfonylureas action is the suppression of hepatic glucose 
production. DeFronzo and Simmons (1984) have demonstrated a 
marked decrease in hepatic glucose production in NIDDM patients 
treated with glyburide, a second generation sulfonylurea. Fleig 
et al. (1984) demonstrated in primary cultured hepatocytes that 
glyburide induced an increase in insulin stimulated glycogen synthesis. 
With the perfused liver preparation, Blumenthal (1977) showed 
a potentiation by chlorpropamide (a first generation sulfonylurea) 
of insulin induced inhibition of glucagon stimulated glucose output. 
Glyburide is able to enhance the sensitivity of perfused rat liver 
to insulin, without altering maximal insulin responsiveness (McGuinness, 
1987). 
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AGING, INSULIN RELEASE AND GLUCOSE METABOLISM 
The high incidence of hyperglycemia in aged human population 
is of significance because of its close relationship to maturity 
onset diabetes mellitus. The impairment of glucose tolerance with 
age was first recognized by Spence in 1920 in humans > 60 years 
old. This original observation was confirmed by numerous authors 
with several different tests of carbohydrate metabolism (Davidson, 
1979). These studies indicate that the decline in glucose tolerance, 
which begins in the third deca^o, continues throughout the adult 
life span (Andres, 1971; Jackson et a l . , 1982). Glucose intolerance 
of aging has attracted increasing attention, however, its mechanism 
is not fully understood. 
Development of a significant impairment in peripheral glucose 
uptake with age has been strongly suggested indicating that muscle 
is the principal site of this impairment (Jackson e_t_ aL , 1982; 
De Fronzo. 1979; Robert ej_ aL , 1982; Fink et_ aL , 1983). Glucose 
tolerance curve is dependent not only on increased peripheral glucose 
uptake but also on decreased hepatic glucose output, enhanced splan-
chnic glucose utilization, and the rate of ingested glucose entry 
into the systemic circulation. Although some authors have suggested 
that glucose absorption is unaffected by aging (Guth, 1968; Kendall, 
1979), other investigators have reported a significant reduction 
in intestinal glucose absorption in elderly (Webster 8 Leeming, 
1975; Feibuch 6 Holt, 1982; Montgomery et_ aL , 1978). However, 
it has been confirmed later on by Rodwin et al . (1986) that suppress-
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ion of HGO (hepatic glucose output) after glucose ingestion in 
elderly compared with young men is delayed in onset, prolonged 
in duration, and slightly greater in magnitude. 
Plasma glucagon level is suppressed after glucose loading 
in the young group, but not in the elderly. In response to hyper-
glycemia, the elderly may develop a loss in A-cell sensitivity 
to suppression together with the decreased B-cell responsiveness 
to stimulation (Chen et a l . , 1985; Draznin et a l . , 1985). However, 
Simonson and DeFronzo did not detect any alteration in glucagon 
suppression with age and conversely, suggested that hepatic glucagon 
responsiveness may increase with age. Factors which may play 
a role in the development of hyperglycemia in aging islets include 
(i) altered insulin biosynthesis and release (i i) altered insulin 
sensitivity and (iii) altered insulin action. The development of 
non insulin dependent diabetes is usually due to impairment of 
pancreatic B-cell function as well as diminished effectiveness of 
insulin's action at its target tissues (Weir, 1982). Similarly, 
the glucose intolerance of aging, which is primarily due to a post 
receptor defect in insulin mediated glucose disposal (Andres 8 
Tobin, 1975; De Fronzo, 1979; Rovve, 1983) and is accompanied by 
decrease in insulin clearance (Minaker et a l . , 1982) has been shown 
to be associated with defectiveness in the primary -cell function 
such as glucose stimulated insulin secretion (Kitahara 6 Adelman, 
1979; Reaven et. aL , 1983; Curry, 1984; Elahi et. al_. , 1985) and 
insulin secretion per B-cell . The age related glucose intolerance 
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is independent of the obesity of the animal (Reaven et^  al_. , 1983). 
There is diminished glucose stimulated insulin release from isolated 
pancreatic islets of Langerhans of the older animals as compared 
to younger controls despite the fact that (i) size of the islet, 
(ii) number of B-cells per islet (iii) number of secretory granules 
per B-cells increases with increasing age and (iv) in aging, the 
proportion of B-cells per islet does not change (Reaven et_ al. , 
1979). Changes in the activity of the islet adenylate cyclase-cAMF 
system and glucose metabolism may play significant roles in the 
regulation and control of glucose-stimulated insulin secretion. Thus, 
the enhanced insulin secretion from islets of rats in late pregnancy 
has been correlated with increased islet cAMP levels and increased 
activities of adenylate cyclase and protein kinase (Green et_ a l . , 
1973; Lipson 6 Sharp, 1978). The blunted insulin release from 
the islets of neonatal rats has been postulated to be secondary 
to an immature islet glycolytic enzyme system (Agren e_t_ al_. , 1976) 
and an immature adenylate cyclase-cAMP system (Grill et a l . , 1975). 
The reduced insulin secretion in the fasted state has been correlated 
with a decrease in the activit ies of the enzymes involved in islet 
glucose oxidation (Malaisse et_ a_L . 1976). 
Studies seeking to determine the biochemical mechanism res-
ponsible for this decreased glucose stimulated insulin release have 
demonstrated that there is an age related diminution in islet adeny-
late cyclase activity (Lipson et^  al_. , 1981a,b) islet glucose oxidation 
(Reaven 8 Reaven, 1980) and islet proinsulin biosynthesis and handl-
ing (Gold et a l . , 1981). 
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EXPERIMENTAL DIABETES MELLITUS 
Alloxan 
Alloxan is a pyrimidine derivative isolated in 1818 by 
Brugnatelli. The interest of the scientists in alloxan stems from 
the discovery of its diabetogenic action. In 1943, Dunn e^ al_. 
reported that alloxan can produce specific islet necrosis in rabbits 
and the term "alloxan diabetes" was introduced by Dunn ej_ a\_. 
(1943) and Goldner 6 Gomori (1943). Alloxan produces diabetes 
by interaction with sulfhydryl enzymes, which are essential for 
the function of the pancreatic B-cell (Lazarow, 1946, 1947, 1949; 
Lazarow et a l . , 1948; Sen 6 Bhattacharya, 1952). Since, both 
monothiols and dithiols were able to protect animals against the 
diabetogenic action of alloxan (Lazarow, 1946, 1947; Lazarow e_t_ 
a l . , 1948), but only dithiols could reverse the action of alloxan 
(Sen 8 Bhattacharya, 1952). The mechanism of enzyme inhibition 
may be the formation of an S-S bridge between essential SH-groups 
(Sen 6 Bhattacharya, 1952). Diabetogenic action of alloxan can 
be protected by the preadministration of glucose and mannose, 
but not by other sugars (Sen fi Bhattacharya, 1952; Bhattacharya 
1954). 3-0-Methylglucose also protected against the diabetogenic 
action of alloxan (Carter 6 Younathan, 1962). Glucokinase is the 
enzyme in the pancreatic B-cell and liver which is most sensitive 
to inhibition by alloxan (Lenzen et_ al_. , 1987; 1988; Miwa ej_ al . , 
1984). Glucokinase may be the primary target for alloxan in the 
pancreatic B-cell responsible for inhibition of glucose - induced 
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Table 6: Glucokinase inh ib i to ry potency of al loxan and var ious 
d e r i v a t i v e s . The half maximal glucokinase inh ib i to ry 
concentration of al loxan was 5 umol/L. This inh ib i to ry 
potency of alloxan was al located the inh ib i to ry potency 
factor of F = 1.U0. A factor F=0 ind ica tes the complete 
lack of inh ib i to ry potency. Data is de r ived from (Lenzen 
et_ al_. ,1988). 
Glucokinase inh ib i to r C-5 Inh ib i to ry potency 
(F = 1.00 = inh ib i t ion by 
al loxan) 
Alloxan 
( 2 , 4 , 5 , 6 - T e t r a o x y p y r i m i d i n e ) 
Uramil 
Violuric acid 
Barb i tu r ic acid 
C=0 
ML 
NO, 
H, 
1.00 
0.20-0.25 
58 
insulin secretion and also for D-cell toxic action of this agent (Lenzcn 
et_ al_. , 1988). 
Streptozocin 
Streptozocin (STZ), a methyl nitrosourea, with a 2-substituted 
glucose, is a pancreatic B-cell toxin that has been widely used 
to induce experimental diabetes inellitus. Streptozocin is isolated 
from Streptomyces acromogenes and have a dose related diabetogenic 
effect but the diabetogenic dose varies considerably between different 
species (Rerup, 1970; Cooperstein 8 Watkins, 1981). Its mechanism 
of action has not been fully elucidated. In a single high dose, 
STZ is believed to act as an alkylating agent and damage the DNA 
of B-cells (Okamoto, 1985; Le Doux 6 Wilson, 1984; Le Doux et_ 
a]_., 1986). Studies examining the effects of multiple injections 
of low ( i . e . subdiabetogenic) doses of STZ in certain strains of 
mice suggest that the thymus dependent, cellular immune systems 
may be involved in at least part streptozocin's diabetogenic effect 
(Like 8 Rossini, 1976; Buschard 8 Rygaard, 1978; Faik e_t_ al . , 
1980; Shin et_ al_. , 1981). The type of diabetes induced by strepto-
zotocin depends upon the route and frequency of administration. 
Thus, neonatal rats administered a single intraperitoneal injection 
of 90 mg/kg body weight of streptozocin develop persistent hyper-
glycemia by 6th week of age and subsequently a diabetic condition 
more or less similar to NIDDM. 
59 
0 
Alloxan 
Streptozotocin 
Fig. 12: Structure of al loxan and s t rep tozotoc in . 
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Table 7: Protective potency of sugars against inhibition of gluco-
kinase by alloxan. The half maximal effective concentration 
of glucose for protection against alloxan inhibition (")0 
jumol L) was around 8 m:.')l.L. 
Sugar Glucose Protective 
potency 
D-Glucose 1.00 
D-Mannose C-2 0.90 
ii 
D-Mannoheptulose C-2 0.90 
D-Glucosamine C-2 amino sp. 0.81 
N-Acetylglucosamine C-2 Ni-acetyl 0.67 
amino sp. 
2-Deoxy-D-glucose C-2 hydrogen group 0.15 
3-0-Methyl-D-Glucose C-3 3-0-methyl group 0.0") 
D-Galactose C-4 0 
I N T R O D U C T I O N 
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Diabetes mellitus has been treated orally with herbal 
remedies based on folk medicine since ancient times. With the 
advancement of knowledge, the importance of plant constituents 
as source of unlimited natural wealth especially in the form of 
drugs and essential oils, has been increasingly recognised. The 
use of different plant constituents as drugs especially in Ayurvedic 
and Unani system of medicine is common in our country. However, 
systematic investigations on the clinical uses of the plant consti-
tuents on scientific lines have only recently been started in various 
laboratories. Nevertheless, no medicine capable of eliciting radical 
cure for diabetes has yet been discovered. Doubts about the 
efficacy and safety of present day oral hypoglycemic agents have 
prompted a search for safer and more effective drugs for the treat-
ment of diabetes. Traditional herbal remedies, which are known, 
by experinece, to be free from side effects, are st i l l used by 
diabetic patients, especially in third world countries and may, 
therefore, represent new avenues in the search for alternative 
hypoglycemic drugs. The discovery of insulin in 1921, followed 
by oral hypoglycemic drugs (sulfonylureas in 1955 and biguanides 
a few years later) has simplified the control of hyperglycemia. 
India being a vast country having extreme geographical and climatic 
diversi t ies provides innumerable plant species and is , therefore, 
ideally suited for scientific investigations on their clinical pro-
pert ies . 
Insulin like activity in (-) epicatechin 
Herbs and plant extracts have been traditionally used 
for controlling diabetes mellitus in folk medicine all over the 
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{—) Epicatechin 
Fig. 13: Structure of (- )cpicatechin. 
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world. Water extract of the bark of Pterocarpus marsupium Roxb 
is being used in Indian medicine for the treatment of diabetes since 
long. The active antidiabetic principle in the water extract has 
been suggested to be a benzopyran, (-) epicatechin (Devon c\_ al. , 
1975; Sawhney et a l . , 1956). It protects normal rat islets from 
alloxan toxicity, brings about normalization of blood glucose level 
and helps B-cell regeneration after necrosis due to alloxan 
(Chakrawarthy et_ al_. , 1980, 1981). Recently Charles S Simon (1984) 
have reported that (-) epicatechin, when administered to ra ts , 
increases insulin secretion and also raises insulin content of the 
is le ts . However, its clinical tr ials on scientific basis have not 
been carried out. 
The present studies describe some insulin like effects of 
(-) epicatechin. when tested on insulin target tissues jri vi t ro. 
With the view to understanding the nature of binding site of (-) 
epicatechin on the target cells, competitive binding studies with 
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I-insulin have been carried out. Studies on conversion of pro-
insulin to insulin and cathepsin B activity in islets of Langerhans 
have also been described in this chapter. 
Coleus forskohlll 
It is perennial aromatic herb that grows throughout the 
plains of India and in subtropical Himalayan regions upto a height 
of 2400 m. It is also cultivated as ornamental plant. The leaves 
of this plant are used for stomach ailments. The dwellers of 
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Coleonol 
Fig. 14: Structure of coleonol. 
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'Tawaghat' Pithoragarh (U.P. , India) know this plant by the name 
of 'Baddh Ki Jarh1 (Bhava Mishra, 1960). In abdominal pain, adults 
chew more than 2 gm of its fresh root and believe that it kills 
the worms of intestine. It is also used as anticonstipative. 
Coleonol, a diterpenoid, was isolated from the roots of 
the plant independently by two different groups, one working at 
CDRI and the other at Hoechst Research Centre, Bombay (India) 
by the name of coleonol (Tandon e^ al_. , 1977) and forskolin (Bhat 
et a l . , 1977) respectively. The diterpenoid was found to activate 
hormone sensitive adenylate cyclase. Hence, this compound is 
an important tool for studying physiological effects of cyclic AMP. 
Primary biological screening of 50% ethanol extract of the roots 
indicated hypotensive and spasmolytic activit ies (Bhakuni el_ al. , 
1971; Dubey et. al_. , 1974; Dubey ej_ a h , 1981). Systematic study 
of this extract has led to the isolation of a diterpenoid (Fig. 14 ) 
(Tandon et_ al_. , 1977; Bhatt et_ _al_. , 1977). which can directly acti-
vate the catalytic subunits of adenylate cyclase (Hermansen, 1985). 
Adenyl cyclase-cAMP system is involved in the release of islet 
hormones (Sharp, 1979; Wollheim ei^ ah , 1976). _In vivo adenylate 
cyclase may be stimulated to increase intracellular cyclic AMP 
levels in B-cell by hormones such as glucagon and this could result 
in insulin release. Forskolin has been found to change the electr i -
cal activity of B-cell membranes (Henquin fi Meissner, 1984). The 
diterpenoid increases cyclic AMP content and insulin release in 
rat pancreatic islets (Wiedenkeller 6 Sharp, 1983). 
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We have studied the effect of coleonol in normal rats on 
insulin and glucagon secretion from islets _in vi t ro . The effects 
of oral feeding of coleonol on blood glucose and free fatty acid 
level as well as on liver glucose-6-phosphatase activity and glycogen 
level have also been studied. 
Effect of age and glucose concentration on the activity of CCK-4 
and its synthetic analogues with respect to insulin and glucagon 
release from islets of Langerhans JJI vitro 
Elevated blood glucose level is common in non diabetic 
elderly population and may be closely related to the development 
of type II diabetes mellitus (Nilson et_ a\_. , 1964; Joffe et_ a h . 
1969; 0,sullivan et_ al_. , 1971; Epstein, 1967; Hayner et_ al_. , 1965). 
Factors which play a role in the development of hyperglycemia 
in aging include (ij altered insulin biosynthesis and its release, 
(ii) altered insulin sensitivity of the target tissues and altered 
insulin actions. Similarly, the glucose tolerance on aging, which 
is primarily due to a post receptor defect in insulin mediated 
glucose disposal (Andres, 1975; De Fronzo, 1979; Rowe el_ a]_. , 1983; 
Fink et_ al_., 1983) and is accompanied by decrease in insulin clear-
ance {Minaker en a\_., 1982), has been shown to bo associated with 
defects in the primary B-cell functions. Glucose stimulated insulin 
secretion and insulin secretion per B-cell decreases with age (Kitahara 
6 Adelman, 1979; Reaven et_ al_. , 1983; Curry e^ al_. , 1984; Elahi 
et al . , 1985), even if the animals are prevented from becoming 
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obese by exercise or caloric restriction (Reaven £t_ a h , 1983). 
There is diminished glucose stimulated insulin release from isolated 
pancreatic islets of Langerhans of the older animals as compared 
to younger controls, despite the fact that the size of the is le ts , 
the number of B-cells per islet and the number of secretory granules 
per B-cells increase with the increasing age without any considerable 
change in proportion of different secretory cells per islet (Reaven 
et al. , 1979). Studies on biochemical mechanism responsible for 
the decreased glucose stimulated insulin release have demonstrated 
that there is an age related diminution in islet adenylate cyclase 
activity (Lipson £t_ al_., 1981a,b) islet's glucose oxidation (Reaven 
6 Reaven, 1980) and islets proinsulin biosynthesis and handling (Gold 
tn al_. , 1981). 
A selective impairment of A-cell response to glucose is 
seen in diabetic as well as in normal aging persons. 
Insulin secretion is directly influenced by the central nervous 
system. Woods andPorte in 1974 showed that sympathetic and para-
sympathetic nervous system may be modulators of alpha and beta 
cell of islets of Langerhans. Some hormonal peptides such as gut 
hormones, gastrin and cholecystokinin play important role as neuro-
regulators. Cholecystokinin, a gastrointestinal hormone has been 
implicated as neurotransmitter influencing hormonal release from 
is le ts . Rehfeld et_ al_. (1980) studied the molecular nature of CCK 
nerve terminals present in the pancreatic i s le ts . The prominant 
form of CCK in these nerves seems to be the C-terminal tetrapeptide 
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amide of cholecvstokinin (Trp-Met-Asp-Phe-NH2) referred to as 
CCK-4. It was observed that amongst varioous cholecystokinins, 
CCK-4 was considerably more effective in releasing islet hormones. 
Biological activity of cholecystokinin and gastrin is closely related 
due to the identical four C-terminal sequences. 
With the view to introducing selectivity in CCK-4 molecule, 
congeners of CCK-4 were synthesized, which may selectively stimu-
late the release of insulin without affecting the release of other 
islet hormones. Structure-activity relationship studies of CCK-4 
(Trp-Met-Asp-Phe-NI-L) and its synthetic congeners were carried 
out on the basis of side chain functionalities as well as by intro-
ducing stereoisomeric changes in amino acids. 
Synthetic analogues of CCK-4 in which N-terminal Trp-residue 
was substituted by cyclic amino ac:ids (Glp or Pro) retain the 
ability to stimulate the release of insulin from isolated islets of 
Langerhans (Ahmed et_ aL , 1984) and have no effect on the release 
of glucagon (Khalid e_t_ aL , 1986). 
In continuation of these studies, seven different synthetic 
analogues of CCK-4 synthesiscd in this institute were studied for 
getting information regarding their specificity in releasing islet 
hormones. Modifications were introduced at 1st, 2nd and 4th position 
of parent CCK-4 molecule, while in three of the analogues C-terminal 
Pro residue was replaced by D-Pro, ^ P r o and Thz (Thiazolidine 
4-carboxylic acid) . 
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Biological activities of CCK-4 and its seven now synthetic 
analogues were studied. Structural details have been given in 
Figs. 16-20. 
CCK-4 
Pept ide 1: 
II: 
I I I : 
IV: 
V: 
VI: 
VII: 
Trp-Met-Asp-Phe-NH 2 
Trp-Met-Asp-Me Phe 
Trp-Ser-Asp-Me Phe 
Pro-Met-Asp-Phe-NHCH3 
D-Pro-Met-Asp-Phe-NH 
Thz-Met-Asp-Phe-NH2 
APro-Met-Asp-Phe-NH 2 
L-Pro-Met-Asp-Phe-NH„ 
In peptide I, the C-terminal residue Phe of CCK-4 is methy-
lated (Trp-Met-Asp-Me Phe). Peptide II (Trp-Ser-Asp-Me Phe) 
has two modifications i .e . in addition to methylated C-terminal 
Phe residue, Met at position 2 is also replaced by Ser. The third 
analogue Pro-Met-Asp-Phe-NHCPL (Peptide III) has also two modi-
fications, Trp being replaced by Pro at position 1 and the C-terminal 
amide is methylated. In peptide IV, Trp being replaced by D-
Pro at position I. In peptide V Trp at Position 1, being replaced 
by Thz (Thiazolidine-4-carboxylic acid) . In peptide VI, Pro 
was substituted at position 1 in place of Trp, while in peptide 
VII, Trp was replaced by L-Pro at position 1 of the CCK-4. Peptide 
I and II were shown to have an inhibitory effect on the release 
of insulin and glucagon while peptide III has stimulatory effect 
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on insulin release and inhibitory effect of glucagon release (Khalid 
en ah , 1989). 
Insulinotropic action of cholecystokinin and its congeners 
(Peptides IV, V, VI) have been studied at stimulatory and non-
stimulatory concentrations of glucose on islets of Langerhans. Effect 
of peptides IV and VII were compared in 1 and 2 month old rats 
regarding insulin release. 
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C- Terminal tetrapeptide amide of cholecystokinin 
[CCK-4 ] 
Fig. 15: Structure of CCK-4. 
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Pept ide l 
[N-methylation at c-terminal] 
H A H H H 
H,N — C C — N — C C — N — C 
3 i n i II I I 
CH2 
I 
OH 
CH2 
COOC 
•c-
II 
0 
Peptide I I 
[Met replaced by 5er at position 28>N-methylation at c-terminal] 
H H H
 H H H H 
® I I I I I I I 
H j N - C — C— N — - C — C — N —C — C — C — N — CH 
I I 'I 
0 HjC CH? 
"CH2 
CH2 
CH2 
s 
I 
CH3 
3 
CH? CH? 0 
i e 
COO 
Peptide I I I 
Trp replaced by P^ o and C-terminal amide Substituted by 
Methyl group 
Fig. 16: (i) Structure of peptide I . Met at position 
2nd of the parent tetrapeptide is replaced 
by Ser and C-terminal is N-methylatcd. 
(ii) Structure of peptide II. The parent tetra-
peptide is N-mothylated at C-terminal. 
( i i i) Structure of poptido III. Trp at position 
1st of tlio parent totrapoptido is replaced 
by Pro and C-torminal amido is substituted 
by methyl group. 
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CH3 Peptide IV 
Trp replaced by D.Pro at position 1st 
Fig. 17: Structure of peptide IV. 
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^ 0 CH2 0 CH2 0 CH2 0 
I I 
CH2 COOH 
S 
I 
CH3 PeptideV 
Trp replaced by Thz at position 1st 
Fig. 18: Structure of peptide V. 
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^ 0 CH2 0 CH2 0 
I I 
CH2 C00H 
I 
S 
CH3 Peptide VI 
Trp replaced by ^ Pro at position 1st 
Fig. 19: Structure of peptide VI. 
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Trp replaced by L-Pro at position 1st 
Fig. 20: Structure of pep t ide VII. 
MATERIALS AND METHODS 
MATERIALS 
Animals 
Animals used in the present s tud ies were de r ived from 
the animal colony of Central Drug Research Ins t i tu t e , Lucknow, 
housed in a i r conditioned rooms. Char les Fos ter albino male r a t s 
maintained on s tandard balanced pel le t diet (Hindustan Lever L td . , 
Bombay, India) and water a_d libitum was used throughout in these 
exper iments . 
Drugs and Chemicals 
Coleonol was isola ted in the Medicinal Chemistry Division, 
C . D . R . I . , Lucknow, India . C-terminal t e t r a p e p t i d e amide of cho le -
cystokinin (CCK-4) and i t s syn the t i c analogues were syn thes ized 
in the Biopolymers Division of th i s Ins t i tu t e . ( - )Ep ica t ech in , 
collagenase type V, aprot in in ( t r a s y l o l ) , bovine serum albumin 
(BSA), al loxan monohydrate , s t rep tozotoc in , glycogen, t heophy l l i ne , 
Eagle ' s medium, g lucose-oxidase and pe rox idase were obtained 
125 from Sigma Chemical Co. , St. Louis, U.S.A. I - insul in (speci f ic 
14 
ac t i v i t y 100 C i / g ) , C-Leucine (speci f ic a c t i v i t y 208 mCi/mmole), 
14 
C-glucose (speci f ic a c t i v i t y 255 mCi/mmole) and insulin r a d i o -
immunoassay ki t were purchased from Bhabha Atomic Research Centre , 
Bombay, India . Glucagon and cyc l ic AMP k i t s were obtained from 
Diagnostic Products Corporation Los Angeles, U.S.A. Bovine zinc 
insulin (6 times c r y s t a l l i z e d ) was obtained from Boots Drug House, 
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Bombay, India. Amino acids, 2,5 diphenyl oxazole (PPO) and 
dimethyl 1,4 bis [2-(5-phenyl oxazole )-benzene] (POPOP) wore 
products of Sisco Research Laboratories, Bombay, India. Sephadex 
G-50 was purchased from Pharmacia Fine Chemicals, Uppsala, Sweden. 
All other reagents and chemicals used were of analytical grade 
(AR). 
METHODS 
Isolation of islets of Langerhans from rat pancreas 
The animals were fasted overnight before sacrifice for 
the removal of pancreas. The islets of Langerhans were isolated 
by collagenase digestion method of Lacy and Kostianovsky (1967). 
Albino male rats of desired weight were injected with pilocarpine 
(60 mg/kg body weight) intraperitoneally, 2 hr before sacrificing 
the animal for the removal of pancreas. The rats were decapitated 
and the pancreas were gently removed by carefully cutting from 
the splenic part towards the duodenal part or vice versa. The 
pancreas was placed in a beaker with ice-cold modified Hank's 
balanced salt solution. After cleaning off the extraneous adipose 
tissue, the tissue was chopped into small pieces. The fine pieces 
were washed several times with HBSS following removal of fats. 
The chopped tissue was allowed to settle down and then collagenase 
4 mg/ml of packed tissue was added. Incubation was carried out 
in scintillation vials . The vials were incubated with vigorous 
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stirring horizontally for 15-20 minutes at 37 C in a metabolic shaker. 
The incubation was terminated by adding 10 ml of HBSS containing 
2 mg/ml BSA to the vials . The islets were picked up by means 
of a pasteur pipette under dissection microscope and transferred 
in Kreb's Ringer Bicarbonate buffer (KRB) containing 2 mg/ml bovine 
serum albumin, 12 naturally occurring amino acids, plus 0.01 M 
non essential amino acids according to Eagle (1959). The time 
of incubation and concentration of collagenase were standardized 
for each batch of collagenase. 
Oxygen uptake studies 
Oxygen uptake studies were carried out in Gilson oxygraph 
(lillson Medlt.nl lilocli utiles Midillciuii, Wisconsin, U'lA) lwivlii)J •) 
Clark type electrode assembly set up. Polarizing voltage applied 
across the probe was -0.8V and sensitivity Knob was set at 160 
mark. Oxygraph was calibrated by incubating deionized water 
in the incubation vessel. Fat cells were isolated from rats by 
collagenase digestion method of Rodbel (1964). Tissue slices of 
hi'-iln, llvor, hofii't, mnsclo and f<\t colls worn Incuhntod In iho 
_3 incubation vessel in Hank's medium with 17.6 mM glucose and 10 M 
(-)epicatechin or 1 mU insulin as desired. The pH of the medium 
was 7.4 and the temperature of the oxygraph cell was maintained 
at 30 C by circulating water. 0„ uptake was recorded on a str ip 
chart recorder and was expressed as ul 0„/mg tissue/hour "Qo?". 
A separate control was also run where no epicatechin or Insulin 
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was added. 0_ uptake was calculated according to Estabrook (1967). 
14 In vitro incorporation of U -C glucose into glycogen in rat diaphragm: 
Pieces of diaphragm weighing about 50 mg were isolated 
from male albino rats of 100-150 g weight and incubated in 1.0 
ml of the incubation medium in which 5 uCi 
14 
U -C glucose (specific activity 255 mCi/mmole) was added. Incuba-
tions were carried out at 37 C for 15, 30, 60 and 90 minutes in 
a metabolic shaker. (- )Epicatechin was added at the concentrations 
-5 -4 -3 -2 
of 10 , 10 10 and 10 M into the incubation medium. Separate 
controls were also run where no epicatechin was added. At the 
end of the incubation period, the medium was carefully removed. 
Glycogen was isolated from the diaphragms and purified according 
to the following method of Fontella (1984). Diphragms were homo-
genized (40 strokes, 1500 rpm) in 1.0 ml of 0.3 N HC1. 100 ul 
aliquots of the homogenates were spread evenly on the surfaces 
of Whatman No. 3 filter paper ( 2 x 2 cm). After absorption, 
the filter papers were immediately transferred into a beaker con-
taining a minimum of 7.0 ml cold 66% (v/v) ethanol. They were 
then briefly rinsed with acetone for 5 min and dried under a heat 
lamp until the odor of the acetone was no longer present. Filter 
paper was placed in a glass scintillation vial containing 10 ml 
of 0.6% (w/v) 2.5 diphenyl oxazole (PPO) and 0.02% (w/v) 1,4-
bis 5-phenyl-2-oxazolylbenzene (POPOP) in toluene and methoxy-
ethanol (1:1) (v/vjand then were counted. 
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Effect of (-)epicatechin on glycogen content in rat diaphragm _in 
vitro 
Pieces of diaphragm weighing about 50 mg were isolated 
from male albino rats of 100-150 g vvt and incubated in 1.0 ml 
of KRB-Eagle's medium, pH 7.4. Incubation was carried out for 
1 hr at 37 C. (-)Epicatechin was added at the concentrations of 
-5 -3 -2 
10 , 10 and 10 M into the incubation medium. At the end of 
the incubation period, the medium was carefully removed. Glycogen 
was isolated from the diaphragms and purified using the method 
of Good e]_ aj_. (1933). According to this method, pieces of dia-
phragms were taken in a pyrex centrifuge tube containing ;u)"u 
KUH solution. The tissue was then digested by heating the 
tube in a boiling water bath for about 20-30 minutes. When the 
tissue was dissolved, saturated sodium sulphate was added and 
the glycogen was precipitated by adding 1.1 to 1.2 vol of 95% 
ethanol. It was heated again until the mixture started boiling. 
The tubes were cooled and then centrifuged at 3,000 rpm for 5 
minutes. The supernatant was decanted. Adhering alcohol was 
expelled by heating the tube in a boiling water bath. The process 
was repeated 3 times. Purified glycogen was estimated according 
to Dubois et aj_. (1956) using 80% phenol and sulphuric acid. 
Isolation of liver plasma membrane 
Liver plasma membranes were isolated according to the 
method of Neville (1968). All steps were carried out between 
0-4 C. The procedure employed was as under: 
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1. Rats weighing about 100 g were decapitated, the l ivers were 
quickly excised, placed in ico cold beaker and minced with 
scissors. 
2. 10 gm of minced liver was placed in a 50 ml homogenizer, 
25 ml media was added and homogenized at 4 C with 8 vigorous 
strokes of the loose pestle. Pooled homogenate was taken 
in a beaker containing 500 ml media at 4 C. After stirring 
for 3 minutes, it was filtered through cheese cloth. 
3. The filtered homogenate was centrifuged at 1500xg max for 
10 minutes and the supernatant was removed. 
4. The pellets were collected and homogenized with 3 gentle 
strokes of the loose pestle. It was then spun down at 13,000xg 
for 10 min and the membranes were collected and washed 
by recentrifugation. They were then taken in a solution 
of 0.25..1 sucrose and 1 mM MgCl2 and floated at 90,000xg for 
2 hr . The pellet was resuspended and applied to a 37-15% 
sucrose gradient containing 1 mM MgCl„. 
Preparation of fat cells 
Fat cells were prepared according to the method of Rodbell 
(1964). Rats were killed by decapitation, the epididymal fat 
pads were removed and rinsed in 0.15% NaCl solution. The thin 
distal portions from each pad were cut into pieces. Upto 1 g of 
the tissue was added to 25 ml siliconized flask containing 3.0 
ml of albumin bicarbonate buffer, 10 mg of collagenase and 3 ^umoles 
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of glucose per ml. Incubations were carried out for 1 hr at 37 C 
in -a metabolic shaker. The tissue was dispersed into small frag-
ments within 1 hr of incubation with collagenase. Fat cells were 
liberated from the tissue fragments by gentle s t i r r ing. Liberation 
of the cells was manifested by an increased turbidity in the medium. 
Fragments of tissue st i l l remaining after this treatment were removed 
with forceps. The suspension of the cells was centrifuged in poly-
ethylene centrifuge tubes for 1 minute at 400xg. The fat cells 
floated at the surface. The stromal vascular cells were removed 
by aspiration. The fat cells were washed with 10 ml of warm 
(37 C) albumin buffer containing glucose by centrifugation for 1 
minute at 400xg. This procedure was repeated 3 times till histo-
logical examination showed fat cells free from stromal vascular 
cells. The floating fat droplets at the surface were aspirated 
after gently stirring the cell suspension . 
125 Binding of I-insulin to liver membranes 
Liver plasma membranes were isolated according to Neville 
125 (1968). I-Insulin (specific activity 100 Ci/g) was used for 
binding to liver membranes according to the method described 
by Rodbell et al . (1971). Purified plasma membrane was taken 
in 1 mM KHCCL containing 150 ug protein and incubated at 30 C 
for 20 minutes with or without unlabelled insulin and (-)epicatechin. 
125 After which, sufficient I-insulin was added to the incubation 
tubes containing 50 ul of Ca free KRB, pH 7.5 (buffer containing 
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bovine serum albumin) to give a final I-insulin concentration 
of 3.0 nM. After incubation for further 40 minutes, 60 ul aliquots 
were removed and layered onto 250 ul of KRB, pH 7.5, containing 
10 mg/ml of albumin in plastic microtubes as described by Freychet 
e± a\_. (1971). After centrifugation (IEC-25, 15000 rpm) for 5 minutes 
at 4 C, the supernatant was discarded and radioactive counts of 
the pellets were registered. 
Release of free-fatty acids (FFA) from fat pads Jjni vitro 
Rat epididymal fat pads were isolated after killing the 
animal by decapitation. Pieces of fat pads (about 20 mg) were 
incubated with 1.5 mM theophylline in calcium and glucose free 
Hank's medium, pH 7.4, containing 4% bovine albumin, at 37°C 
with or without (-)epicatechin or insulin. Samples were incubated 
for 90 minutes. FFA released were estimated at the end of the 
incubation period according to Dole's method (1956) as modified 
by Trout et_ al_. (1960). 
Incubation of islets of Langerhans with (-)epicatechin 
The islets of Langerhans were isolated according to the 
collagenase digestion method of Lacy and Kostianovsky (1967). 
Group of 5 islets of comparable size were placed in a flask and 
incubated in 1 ml KRB-Eagle's medium, pH 7.4, with 2 or 20 mM 
glucose. The incubation was carried out with or without (-)epica-
techin at 37 C, for 1 hr in a metabolic shaker (72 oscillations 
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per minute). Glucagon release and cellular cyclic AMP content 
were measured on the same batches of islets in the supernatant 
and the islet pellets. Samples were drawn from the media for 
glucagon assay employing the method of Hazzard et al_. (1968). 
Rinsed islets were immediately frozen and stored. The frozen islets 
were homogenized with 1.0 ml of ice-cold 5% trichloroacetic acid 
and after centrifugation at 4°C and 4,000xg for 15 minutes, the 
supernatant was collected. It was extracted with ether acidified 
with 0.1 N HC1. The upper ether layer was aspirated and discarded, 
The aqueous phase was dried. Cyclic AMP was extracted according 
to the method described by Brown et_ al_. (1971) and assayed by 
the method of Gilman (1970) as modified by Tovey et_ aL (1974). 
Effect of (-)eplcatechin on cyclic AMP content In Islets of Langerhans 
In vitro 
Group of 5 islets of comparable size were placed in a 
flask containing 1 ml KRB-Eagle's medium, 0.2% BSA, 12 naturally 
occurring amino acids, 2 mM glucose and equilibrated for 45 minutes. 
Subsequently, batches of islets were incubated for 10 minutes in 
the presence of different glucose concentration (2 or 20 mM) and 
epicatechin. cAMP was extracted and assayed as described ear l ier . 
Effect of (-)epicatechin on cathepcin B activity in islets of 
Langerhans _in vitro 
60-70 islets were isolated from the rat pancreas and incu-
bated with 1 mM (-)epicatechin for 1 hr at 37°C in a metabolic 
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shaker as described earl ier . After completion of the incubation 
period, medium was removed and the islets were washed with 
0.15M KC1. The islets were then homogenized for assay of cathepsin 
B -act ivi ty . Washed islets were then homogenized in 2 ml cold 
KC1 (0.15 M) using a power driven Potter Elvehjem homogenizcr 
fitted with teflon pestle at 6,000 rpm (IEC, Bombay, India). The 
homogenate was frozen and thawed for 8-10 times to rupture the 
membrane of lysosomes. 
Enzyme assay 
Cathepsin B (E.C. 3.4.22.1) 
Cathepsin B activity in the islet homogenates was assayed 
according to the procedure based on the modified method (Myceck, 
_2 1970) of Anson (1938). Bovine hnmoglobin (1.5x10 M) was used 
as a substrate. The reaction mixture contained: 0.4M citrate buffer, 
pH 5.0, 0.07 M cysteine HCl in water, pH 3.5 and adjusted to 
pH 5.0 with NaOH. The reaction mixture was allowed to equilibrate 
at 37°C for 5 minutes. At the end of preincubation, the enzyme 
solution was added. Incubation was continued at 37 C for 10 minutes 
after addition of the enzyme. The reaction was stopped by adding 
1 ml 5% TCA. It was filtered through Whatman No.3 filter paper 
to remove the denatured material. The absorption spectrophotmetric 
reading of the clear filterate was recorded at 280 nm. 
"Unit" of cathepsin B activity is expressed as amount 
of enzyme liberating one micromole of tyrosine per minute. The 
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specific activity is expressed as units of enzyme/mg protein. 
Radioimmunoassay of insulin 
Radioimmunoassay of insulin was carried out using RIA 
kit developed by Bhabha Atomic Research Centre, Bombay (India), 
according to the method of Morgan and Lazarow (1963). Human 
insulin was used as the standard. 
Method: 0.3 ml EDTA-phosphate buffer (0.01 M EDTA, 0.04M phos-
phate, pH 7.4) containing 0.5% BSA (w/v) was mixed with 0.1 
ml of standard insulin or unknwon samples and 0.1 ml of antibody 
(anti-insulin guinea pig serum diluted 1:1000,00 times) and kept 
— overnight at 4°C. 0.1 ml of second antibody (anti-guinea pig 
t'-globulin raised in rabbit) was then added. Complete antigen-
antibody precipitation was achieved by adding 1 ml of 12% poly-
ethylene glycol-6000 into the tubes containing the antigen-antibody 
complex. The tubes were centrifuged at 4,000 rpm for 20 minutes 
and radioactive counts in the precipitate was counted in LKB auto-
gamma spectrometer. Appropriate controls for nonspecific binding 
125 
of insulin was also run and total insulin count in I-insulin sample 
was determined. Dose response curve of insulin concentration against 
percent binding was plotted. The results were expressed as jull/ml 
or is le ts . 
Radioimmunoassay of glucagon 
Radioimmunoassay of glucagon was carried out using RIA 
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kit (Diagnostic Products Corporation, Los Angeles) according to 
the method of Hazzard et. a]_. (1968). 
Method: 0.2 ml of the sample or standard was mixed with 0.1 
ml. of glucagon antiserum and incubated for 24 hours at 2-8 C. 
125 This was followed by the addition of I-glucagon with vigorous 
stirring on a vortex mixer. The tubes were again incubated for 
24 hours at 2-8 C. 1.0 ml of goat antirabbit V-globulin was added 
to precipitate antigen-antibody complex. The tubes were centrifuged 
at 1500xg for 15 minutes. The supernatant was removed retaining 
the precipiate for counting of radioactivity. Each tube was counted 
for 1 minute. Control in duplicate for non specific binding of 
125 125 
I-glucagon was also run and total counts in the I-glucagon 
samples were determined. The results were expressed as pg/5 
i s le ts /hr or pg/ml. 
Radioimmunoassay of cyclic AMP 
Radioimmunoassay of cyclic AMP was carried out using 
RIA kit (Diagnostic Products Corporation, Los Angeles) according 
to the method of Tovey et_ al_. (1974). 
Method: Into 0.1 ml of standard cAMP or unknown samples in 
a test tube was added 1.0 ml of Tris-EDTA buffer, pH 7.5. After 
3 
vortex mixing, 100 ul of H cAMP was added and mixed again by 
vortex. After thorough mixing, 100 ul of cAMP binding protein 
was added to it and put to vortex again. The tubes were then 
91 
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Fig. 23: A typical s tandard curve for the radioimmunoassay 
of cAMP. 
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put in an ice-bath at 0 C for at least 90 minutes in order to equi-
librate the temperature of the reaction mixture. 0.5 ml of ice-
cold charcoal-dextran suspension was then added into the tubes 
and the contents were mixed by vortex and kept for further 10 
min at 0 C in the ice-bath. It was then centrifuged for 20 minutes 
at 2,000xg. The charcoal packed firmly at the bottom of the 
tube. The radioactive counts were registered in the supernatant. 
Studies on the conversion of proinsulin to insulin by (-)epicatechin 
in vitro and effect of age thereon 
Incubation procedures: Approximately 60-70 islets from 1 and 
12 month old rats were taken in each vial and incubated in final 
volume of 1 ml KRB containing 16.7 mM glucose, 0.2% BSA, trasylol 
(1000 KlU/ml), naturally occurring amino acids (except leucine) 
according to Eagle (1959), and 50 uCi of C-Leucine (specific 
activity 208 mCi/mmole). (- )Epicatechin (1 mM) was added in 
the experimental tubes. The media was gassed with 95% O- and 
5% CCL ( v / v ) . Incubation was carried out for 2 hrs in a metabolic 
shaker. 
Extraction of islet protein: Since- no significant release of pro-
insulin takes place before 200 min of incubation, the incubation 
medium in which the islets were incubated was discarded. The 
islets were ruptured by freeze and thawing (in liquid air) and 
subjected to homogenization in cold TCA (10% w/v) . It was then 
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centrifuged. The sediment was extracted twice with acid nthannl 
(ethanol:0-phosphoric acid:water: 80:1:19 v/v/v)for a total period 
of 20 hrs (Davoren, 1962). The two extracts were pooled and 
the residue was dissolved in IN sodium hydroxide. Suitable al i-
quots of both the fractions were added to scintillation vial containing 
10 ml of scintillation fluid (0.4% PPO and 0.01% POPOP in toluene: 
2-methoxyethanol; 1:1 v/v and counted in LKB liquid scintillation 
spectrometer. The radioactive counts in the extract were taken 
14 
as an index of C-Leucine incorporation into (Pro)insulin fraction. 
The (Pro)insulin fraction extracted with acid ethanol was evaporated 
to dryness in vacuo and the residue was dissolved in 1 ml of 
0.02M borate buffer pH 7.6. It was then applied to a column 
of Sephadex G-50 (1.5x50 cm) pre-equilibrated with 0.02M borate 
buffer, pH 7.6. 
Characterization of biosynthetic product 
The radioactivity was measured in 0.1 ml sample of each 
fraction in 13 ml scintillation fluid (0.4% PPO and 0.01% POPOP 
in toluene: 2 methoxyethanol, 1:1 v/v) and counted in LKB liquid 
scintillation spectrometer. The immunoreactive insulin and proinsulin 
contents of the samples were determined after appropriate dilution 
in phosphate buffer (pH 7.4) containing 0.2% BSA. Fractions were 
also monitored for protein by absorption at 280 nm in spectronic-
21 (Bausch 6 Lomb, U.S.A.) spectrophotometer. 
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Treatment of proinsulin fractions with cathepsin B 
Proinsulin fraction isolated after passing through the sephadcx 
G-50 (1.5x50 cm) column was treated with 50 ug and the reaction 
was stopped by adjusting the pH to 2.0. The solution was then 
passed again through a Sephadex G-50 column, pre-equilibrated 
with 0.02M borate buffer. Absorbance at 280 nm was recorded 
and biologically active insulin was assayed in different peaks. 
Incubation of islets of Langerhans with coleonol for studies on 
insulin and glucagon release jji vitro 
Rats were fasted overnight before they were sacrificed 
for the removal of pancreas. Islets of Langerhans were isolated 
by collagenase digestion method of Lacy and Kostianovsky (1967) 
as modified by Feldman and Chapman (1975). Group of 5 islets 
were incubated with different concentrations of coleonol separately 
in 1 ml KRB-Eagle's medium containing 2.8 or 5.6 mM glucose. 
Experiments for each concentration of coleonol were run in duplicate 
and a separate control (without coleonol )for each experiment was 
run. Incubations were carried out at 37 C in a metabolic shaker 
at pH 7.4 for 1 hr after which samples were drawn for the assay 
of insulin and glucagon employing the methods of Morgan and Lazarow 
(1963) and Hazzard et_ al_. (1968) respectively with minor modificat-
ions wherein polyethylene glycol was used to separate bound and 
free antigen. 
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Oral glucose tolerance test in alloxan diabetic rats 
Diabetes was induced in Charles Foster male albino ra t s 
(200-250 g body weight) by intravenous adminis t ra t ion of alloxan 
(50 mg/kg body weigh t ) . Diabetes was confirmed after 24 hours 
by test ing blood glucose l eve l s using glucose indica tor s t i ck s (Ames 
Division, Miles L t d . , Ind ia ) . The animals were d iv ided into th ree 
groups, namely, normal control , al loxan d iabe t i c control , and coleonol 
t reated alloxan d iabe t ic group. Alloxan d iabe t i c r a t s were fed 
with coleonol ora l ly after overnight fasting 30 minutes before the 
feeding of glucose. Glucose tolerance test was ca r r i ed out according 
to Duffy £t_ al_. employing 1.75 g glucose/kg body weight. The 
blood was withdrawn at ze ro , one, two and th ree hours after glucose 
adminis t ra t ion . Blood glucose was est imated by the glucose ox idase -
perox idase method of Huggot 6 Nixon (1957). 
Assay of serum glucagon level 
Glucagon level in the serum of a l l the th ree groups of 
r a t s was est imated by the radioimmunoassay desc r ibed e a r l i e r and 
re su l t s are expressed as pg/ml . 
14 
C-Leucine incorporation into (Pro)insulin by coleonol 
For in v i t ro s t u d i e s , 60-70 i s l e t s were isola ted from over -
night fasted male albino r a t s . I s l e t s were incubated in a final 
14 
volume of 1 ml KRB-Eagle's medium containing 50 uCi of C-Leucine 
(specif ic ac t i v i t y 208 mCi/mmole) 16 7 mM glucose and 3 ,uM coleonol. 
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During the incubation, the reaction tubes were gassed with 5% C09 
and 95% CL (v/v) for 2 hrs in a metabolic shaker. Cycloheximidc 
control was also run simultaneously where 10 ug/ml of cycloheximide 
was added in the incubation medium. After incubation, islets were 
processed as described earl ier . The results are expressed as 
cpm/mg islet protein. 
Blood glucose, serum insulin, glucagon and free-fatty acid levels 
in normal rats 
Normal rats were treated with coleonol for 7 days (10 
mg/kg body weight) and blood was withdrawn from the retro-orbital 
plexus of overnight fasted ra ts . Blood glucose was estimated by 
the glucose oxidase-peroxidase method of Huggot and Nixon (1957). 
Radioimmunoassay of serum insulin was done according to the method 
of Morgan and Lazarow (1963) and expressed as ^U/ml. Serum 
glucagon was assayed according to the method of Hazzard en aj_. 
(1968). The results are expressed as pg/ml. Serum free-fatty 
acid level was estimated according to Dole's method as modified 
by^ Trout £t_ al_. (1960). 
Liver glycogen level and glucose-6-phosphatase (E.C.3.1.3.9) activity 
Liver glycogen was isolated and purified according to the 
method of Good et^  al_. (1933) and estimated according to Dubois 
et al . (1956). Glucose-6-phosphatase (D-glucose-6-phosphate phos-
phohydrolase, E.C. 3.1.3.9) activity was estimated according to 
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Hubscher and West (1965). The reaction mixture contained 0.1M 
citrate buffer, pH 6.5, 0.03M glucose-6-phosphate, 4 mM EDTA 
and 2 mM sodium fluoride. The reaction mixture was incubated 
for 20 minutes at 37 C. The Pi liberated was estimated according 
to Fiske 6 Subbarow (1925). Enzyme unit is expressed as ^jmole 
Pi liberated/min. 
Cathepsin B and acid phosphatase activity in islets of Langerhans 
in vivo 
Cathepsin B (E.C. 3.4.22.1) 
Normal male rats of about 100-150 g wt were fed coleonol 
(10 mg/kg body weight) for 7 days. Islets were isolated from 
the pancreas of overnight fasted ra t s . 60-70 islets were homogenized 
in 2.0 ml of 0.15M KC1 and cathepsin B activity was assayed accord-
ing to Myceck (1970) as described ear l ier . 
Acid phosphatase (E.C. 3.1.3.2) 
Acid phosphatase activity was assayed according to the 
method of Bessey ej_ al_. (1946). The enzyme sample (75-80 ug 
protein) was incubated in a medium containing 4 uM disodium p-
nitrophenyl phosphate in 0.01 N HCl; 100 mM acetate buffer, pH 
5.0 and 20 mM EDTA at 37 C for 30 minutes. The reaction was 
stopped by adding 2 ml of 0.1N sodium hydroxide. The released 
p-nitrophenol was recorded at 400 to 430 nm. 
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method of Bessey et_ a\_. (1946). The enzyme sample (75-80 ug 
protein) was incubated in a medium containing 4 uM disodium p-
nitrophenyl phosphate in 0.01 N HCl; 100 mM acetate buffer, pH 
5.0 and 20 mM EDTA at 37°C for 30 minutes. The reaction was 
stopped by adding 2 ml of 0.1N sodium hydroxide. The released 
p-nitrophenol was recorded at 400 to 430 nm. 
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Enzyme 'Unit' is expressed as phosphatase activity l iberat-
ing one nmole of p-nitrophenol per minute. The specific activity 
has been expressed as units of enzyme/mg protein. 
Oxygen uptake studies in liver mitochondria 
Fractionation of liver mitochondria: 
About 15.0 ml of 10% homogenate in 0.88 M sucrose was 
centrifuged 10 min at 3,000 rpm to sediment the nuclei; unbroken 
liver cells and red blood cells. The supernatant was centrifuged 
for 10 minutes at 13,000 rpm to sediment the mitochondria. The 
sediments were washed twice by resuspension in 8.0 ml of 0.88 
M sucrose and resedimentation for 20 min at the same speed. The 
washed sediment was resuspended in 0.88M sucrose. 
Incubation of mitochondria in the vessel of oxygraph 
0„ uptake studies were carried out in Gilson oxygraph 
(Gilson Medical Electronics Middleton, Wisconsin, U.S.A.) as des-
cribed earl ier . Mitochondria from coleonol treated rat liver and 
normal rat liver were isolated and incubated in the oxygraph vessel. 
About 50-60 ug of liver mitochondria was used for incubation. 0„-
uptake was recorded on a s t r ip chart recorder and was expressed 
as pi Oy'mg protein/hr "Qo2 Pro". 0„ uptake was calculated accord-
ing to Estabrook (1967). 
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Effect of CCK-4 tetrapeptides on insulin and glucagon release from 
islets of Langerhans jri vitro 
The animals were fasted overnight before they were sacri-
ficed for the removal of the pancreas. The islets of Langerhans 
were isolated by collagenase digestion method of Lacy and Kostianovsky 
(1967) as modified by Feldman and Chapman (1975). Groups of 
5 islets were incubated with 10" , 10" and 10" M concentrations . 
of CCK-4 and its synthetic congeners, D.Pro-Met-Asp-Phe-NH„ (IV), 
Thz-Met-Asp-PheNH2 (V), APro-Met-Asp-Phe-NH (VI) in a flask 
containing 1 ml ot KP.B-Eagle's medium. The incubation was carried 
out at 37 C, pH 7.4, for 1 hour in a metabolic shaker (72 oscilla-
tions per minute) in an atmosphere of 95% 0„ and 5% CCL. Samples 
were drawn from the media after the completion of incubation period 
for the radioimmunoassay of insulin and glucagon. 
Effect of age, glucose and CCK-4 analogues on insulin and glucagon 
release from islets of Langerhans ^ vitro 
Islets of Langerhans were isolated from 1 and 12 months 
old ra ts . Groups of 5 islets of 1 or 12 months old rats were 
incubated with CCK-4 and its synthetic congeners D-Pro-Met-Asp-
Phe-NH (IV), L-Pro-Met-Asp-Phe-NH2 (VII) using 10"10 , 10"8 and 
10 M concentrations. Islets were incubated in KRB-Eagle's medium, 
pH 7.4 with 2 and 20 uiM glucose concentrations at 37 C for 1 hr 
and samples were processed as described ear l ier . 
R E S U L T S 
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EPICATECHIN 
Effect of (-)epicatechin on oxygen uptake In tissues and fat cells 
In vitro 
The oxygen uptake in various tissues and fat cells of 
rats in the presence and absence of (-)epicatechin is shown in 
Fig. 24 • At one millimolar concentration of (-)epicatechin, oxygen 
uptake increased significantly (45 fold in fat cells , 2.7 fold in 
l iver, 3.16 fold in muscle and 3 fold in hear t ) , as compared to 
the respective controls (without epicatechin). However, no increase 
in oxygen uptake was observed in the case of brain tissue. For 
comparison, control experiments were carried out with 1 mU of 
insulin (Fig .74). Insulin caused significant stimulation of oxygen 
uptake (27.2 fold in fat cells , 3.64 fold in l iver, 3.44 fold in 
muscle and 2.3 fold in hear t ) . Thus, there was a comparable 
stimulation of oxygen uptake at 1 mM (-)epicatechin and 1 111U 
insulin. The stimulation of oxygen uptake in different tissues 
and fat cells was blocked by sodium azide. 
Effect of (-)epicatechin on glycogen content of rat diaphragm and 
14 incorporation of U -C glucose into diaphram glycogen jii vitro 
Pieces of rat diaphragm were incuabted with or without 
(-)epicatechin in KRB-Eagle's medium. (-)Epicatechin caused an 
increase in the glycogen content of rat diaphragm in a dose depen-
dent manner. As shown in the Fig. 25. there was 44.3, 134.43 
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and 31U percent increase in the glycogen content of rat diaphragm 
when incubated with increasing concentrations of (-)epicatechin. 
_2 The maximum glycogen content was observed at 10 M concentration 
of (-)epicatechin, where the content was raised from 0. i34±0.075 
to 1.37+0.195 mg/gm of tissue (P<0.001). 
14 The compound stimulated the incorporation of U -C glucose 
into glycogen of rat diaphragm in a dose related manner. There 
14 
was 6,28,66 and 91 percent increase in the incorporation of U -C 
-5 -4 
glucose into glycogen at (-Jepicatechin concentration of 10 , 10 
-3 -2 
10 and 10 M respectively (Fig.26,27). (-)Epicatechin stimulated 
biosynthesis of glycogen was found to be linear upto one hour 
of incubation (Fig. 28). 
Effect of (-)epicatechin on lipolysis in epididymal fat pads in 
vitro 
Rat epididymal fat pads were isolated after killing the 
animal by decapitation. Lipolysis was induced by incubating the 
epididymal fat pads with 1.5 mM theophylline in KRB Eagle's medium. 
As shown in the Fig. 29. (-)epicatechin caused inhibition of theo-
phylline induced lipolysis in a dose dependent manner. Keeping 
the theophylline concentration (1.5 mM) constant, maximum inhibition 
_3 (about 61%) of lipolysis was observed at 10 M concentration of 
(-)epicatechin, while with 1 mli of insulin (in place of (-)epicate-
chin), 74% inhibition of lipolysis was observed. 
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• • Experimental 
Incubation time in minutes 
Fig. 28: Effecl, of incubation time on incorporation 
of Li -C glucose into glycogen of rat dia-
phragm j_n vi t ro . Bars represent the mean 
(±S.D.) of 6 experiments. 
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100 -
0-50 ~ 
D CONTROL 
0 INSUUN(mu) 
0 EPICA7EXHINIM) 
X 
X 
10~3 10~5 10~6 
• Theophylline 1 -5mM. 
Effect of ( - ) ep ica t ech in on l i p o l y s i s in 
ep id idymal fat pads jxi v i t r o . L ipo lys i s 
was induced by incubation of fat pads 
with 1.5 mM theophy l l i ne . Bars r ep resen t 
the mean (± S.D.) of 6 expe r imen t s . 
*P<0.001 
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125 Effect of ( - )epicatechin on the binding of I-insulln to the l i v e r 
cel l plasma membrane 
Binding exper iments were ca r r i ed out by incubating rat 
l i ve r plasma membrane with 3x10 M I - insu l in . About 21% of 
the r ad ioac t iv i t y was found to bind to the membranes. However, 
addi t ion of 10 ng/ml of nat ive insulin caused 19% inhib i t ion in 
125 the binding of I - insul in whereas , near ly complete inhib i t ion 
in the binding of label led insulin was observed in the presence 
of h igher concentration of nat ive insulin (100 ng /ml ) . The competi-
125 t ive binding s tud ies with ( - ) ep ica tech in and I- insul in were 
ca r r i ed out with increasing concentration of ( - ) ep i ca t ech in in the 
125 
medium keeping the concentration of I - insul in constant . The 
125 
re su l t s did not show any significant change in the binding of I-
insulin to the membranes in the presence of increasing concentration 
of ( - ) ep ica tech in (Table 8 ). 
Effect of ( - )epicatechin on glucagon release from Is le ts of Langerhans 
In vitro 
Table 9 shows the pa t te rn of glucagon re l ease by ( - ) e p i c a t e -
chin. It was observed that ( - ) ep i ca t ech in , had no effect on glucagon 
re lease even at h igher concentrat ions of the compound (1 mM) in 
the presence of .'. u n\! glucose in the medium. 
Effect of ( - )epicatechin on cyc l i c AMP content 
Fig.30 shows the effect of different concentrat ions of 
( - ) ep ica tech in on i s le t cyclic-AMP content. There was a concentra t -
Table 8 : Displacement of 
by ( - ) ep ica tech in 
Additions Concentration 
Nil 
Insulin 10 ng/ml 
100 ng/ml 
-2 ( - )Epica tech in 10 M 
10~3M 
10"DM 
-9 10 M 
Each resul t is expressed as 
ments ± S.D. 
r5 
I- insulin binding to l i v e r membranes 
Specific binding % Inhibi t ion 
f 125T . . . of I - insul in 
24300H150 
19650+1060 19.0 
1890+400 92.0 
2-3700+1390 00.0 
24b50±1560 00.0 
24900+1050 00.0 
24700±1270 00.0 
mean of four indiv idual e x p e r i -
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Table 9: Effect of ( - )ep ica tech in on glucagon re l ease from i s l e t s 
of Langerhans in v i t r o . 
Glucose cone. Concentnration of Rate of glucagon re lease 
(mM) (- )epicatechin (pg/5 i s l e t s / h r ) 
Nil 115±12.5 
do 10"2 109H0.2 
do 10"3 12U15.0 
do 10"5 117+17.5 
Results a re exp res sed as mean±S.D. for four different obse rva t ions , 
I l l 
ion dependent increase in the islet cyclic AMP content. The effect 
of (-)epicatechin was studied in the presence of 2.0 (nonstimulatory) 
and 20 mM (optimal) glucose concentrations. Islets were incubated 
with 200, 400, 600, 800 6 1000 ,uM (-)epicatechin in the medium. 
It was found that (-)epicatechin causes a significant Q dose depend-
dent increase in islet cyclic AMP content at both the concentrations 
of glucose. At 1 mM concentration of (-)epicatechin, cAMP content 
was raised from 6.2+0.6 to 19.2±1.7 fmole/Islet (3.1 fold increase, 
P •< 0.001) in the presence of 2 mM glucose and from 16. 2±1.7 to 
34.6±1.5 fmole/islet in the presence of 20 mM glucose (2.13 fold 
increase, P<0.001). 
Effect of (-)epicatechin on cathepsin B activity in islets of 
Langerhans ^n vitro 
TablelO shows the effect of (-)epicatechin on the activity 
of cathepsin B in isolated islets of Langerhans J£ vi tro. Incubation 
of rat islets with 1 mM (-)epicatechin for 2 hrs caused 2.26 fold 
increase in the islets cathepsin B activity over the control (without 
epicatechin). 
Studies on (-)epicatechin stimulated conversion of proinsulin to 
insulin 
Identification of proinsulin and insulin peaks by gel filtration 
Incubation of islets of Langerhans in Kreb's Ringer bicar-
bonate medium containing 50 uCi C-Leucine (sp . activity 208 
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• 2 mM glucose 
E3 20 mM glucose 
@ 2 mM glucose+{-) epicatechin (/iM ) 
B 20 mM glucose • (- ) epicatechin ( / J M ) 
J, 
- 200 400 600 800 
(-) epicatEchin (juM ) 
1000 
30: Effect of glucose and (- )epicatechin on cAMP 
level in i s l e t s of Langerhans jri v i t r o . The 
bars represen t the mean (±S.D.) of 4 exper iments , 
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Table 10: Effect of (-)epicatechin on cathepsin B activity in islets 
of Langerhans _iri vi t ro. 
Cathepsin B* 
Control 0.185±0.02 
Experimental 0.418±0.05 
Results are expressed as mean ± S.D. for six different observations. 
*^imoles of Tyrosine released/mg protein/min. 
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mCi/m mole) and subsequent fractionation by passing through Sephadcx 
G-50 column (1.5 x 55 cm) gives distinct peaks, (Fig. 31 ,Vo 
for void volume, P for proinsulin and I for insulin). Approximately 
75% of the radioactivity incorporated into the islets was detected 
in proinsulin and insulin peaks. Proinsulin fraction obtained after 
passing through the Sephadex G-50 column was pooled, dried 
and reconstituted. Digestion of proinsulin with 50 ug/ml of cathepsin 
B, converted pooled proinsulin fraction to insulin as characterized 
by elution volume of insulin and by radioimmunoassay. On the 
other hand, no effect was observed in the pooled fractions of 
insulin, when incubated with (50 ug/ml) cathepsin B. Most of the 
insulin was eluted between 50-70 ml of the effluent and proinsulin 
was eluted between 25-40 ml of the effluent (Fig. 32) . 
(-)Epicatechln stimulated conversion of proinsulin to insulin and 
effect of age thereon 
Fractionation of proinsulin and insulin after incubation 
of islets with (-)epicatechin shows that conversion of proinsulin 
to insulin is stimulated quite significantly in 1 month old rats 
as compared to 12 month rats (POL001). Percentage of proinsulin 
content in one month control animals was 18.74%. However, when 
the islets were incubated with (-)epicatechin, the proinsulin content 
was reduced to 12.1% in 1 month rats i s le ts . Hence, incubation 
of iselts of Langerhans with (-)epicatechin registered a decrease 
of 35.43% in the proinsulin content. However, (-)epicatechin showed 
115 
T 
15 20 25 
FRACTION NO. 
r 
30 
Fig. 31: Gel filtration of acid ethanol soluble proteins 
on Sephadex G-50 column. Islets were incubated 
for 2 hrs , extracted with acid ethanol and sub-
jected to gel filtration as described in the text. 
VO, P and I represent void volume, proinsulin 
and insulin respectively. 
O-U-i 
PROINSULIN INSULIN 
15 
T 
23 
i 1 r 
31 32 33 
FRACTION NO. 
i r 
34 35 
Fig. 32: Gel filtration of proinsulin on Sephadex G-50 column 
after treatment with cathepsin B (50 jug/ml). 
O i 
11 
FRACTION No. 
33: Effect of (-)epicatechin (1 mM) on islets pro-
insulin/insulin after incubation for 2 hrs in vi tro. 
(Pro)insulin was extracted with 
and fractionated on Sephadex G-50 
equilibrated with IN-acetic acid. 
(0) (-)epicatechin treated. 
Size of the column 1.5x50 cm. 
Flow rate 1 ml/4 min 
acid ethanol 
column, pro-
(•) control. 
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20-
i 
10- X 
1 monfh 12 months 
34: Effect of age on the r e l a t i v e content 
of proinsul in when i s l e t s were incubated 
with or without ( - )ep ica tech in (1 mM). 
Bars represen t the mean (±S.D.) of 6 
exper iments in which is le t ex t r ac t was 
fractionated on Sephadex G-50 jcolumn 
to sepa ra t e proinsul in from insul in. 
Control (0) 
Experimental (•) 
90 -
80 
H Control 
• (") Epicat echin treated 
X 
X 
X 
X 
1 month 12 month 
Effect of age on the r e l a t i v e content of insulin when 
i s l e t s were incubated with or without ( - ) c p i c a t e c h i n 
(1 inM). Is le t e x t r a c t was fract ionated on Sephadex 
G-50 column to s e p a r a t e insulin from p ro insu l in . Bars 
r ep re sen t the mean (±S.D.) of 6 e x p e r i m e n t s . 
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a less stimulatory effect on the conversion of proinsulin to insulin 
in 12 months old rat islets as compared to islets from younger 
rats (1 month). (-)Epicatechin caused 9.4% more conversion of 
proinsulin to insulin in 1 month-old rat islets as compared to 
the conversion observed in 12 months old rat i s le ts . 
Effect of age on (-)epicatechin stimulated Insulin release from 
islets of Langerhans is\ vitro 
Insulin release from the islets of Langerhans of 1 and 
12 months old rats is shown in Fig. 36 . At stimulatory (20 rnM) 
and non stimulatory (2 mM) concentrations of glucose in the medium, 
1 mM (-)epicatechin stimulated the release of insulin quite signi-
ficantly. However, (- )epicatechin and glucose stimulated insulin 
release was decreased with the increase of the animal's age. 
Thus in the case of one month old rat islets insulin release in 
the presence of 1 mM (-)epicatechin at nonstimulatory concentration 
of glucose (2 mM) was stimulated to 97±3.2 ^IU/5 Is lets /hr (as 
compared to the control value 38±3.8 ,uIU/5 Is le t s /hr . P< 0.001). 
The release of insulin from 12 month old rat islets amounted to 
only 61±4.3 uIU/5 i s le ts /hr (compared to 39.8±3.9 AiIU/5 Is le t s /hr , 
P<0.001). It appears that (-)epicatechin induces 1.59 fold increase 
in insulin release in islets from 1 month old rats over that of 
12 month old rats (P<0.001). 
Insulin release in the presence of 20 mM glucose concentrat-
ion in the incubstion medium was increased to 84±6.5 / J IU /5 i s le t s /hr 
D 2 mM glucose 
• 20 mM glucose 
0 2 mM glucose+ ( - ) 
epicatechin (ImM) 
• 20 mM glucose + (-) 
epicatechindmM ) 
1 month 12 months 
36: Effect of age on (- )epicatechin stimulated 
insulin release from islets of Langerhans 
in vitro. The bars represent the mean 
JtS. D. ) of 6 experiments. 
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in one month old ra t s as compared to 65 + 4.3 ^iIU/5 i s l e t s / h r in 
12 months old r a t s . However, the insulin r e l ease in the presence 
of 1 mM (- jepica techin and 20 mM glucose from i s l e t s of 1 month 
old r a t s was st imulated to 129+4.8 ,uIU/5 i s l e t s / h r (compared to 
84 + 6.5 ull' 5 i s lo ts hr in 1 mo rat's(l 'v'0.001 ). From the Fig. Jb . i t 
would appear that ( - ) ep ica tech in induces 1.45 fold increase in 
insulin re lease in i s l e t s from 1 month old r a t s as compared to 
that of 12 months old r a t s (P< 0 .001) . No difference in insulin 
re lease was observed at nonstimulatory (basa l ) concentration of 
glucose in 1 and 12 month old rat i s l e t s of Langerhans. 
COLEONOL 
14 Effect of coleonol on C-leucine incorporation into proinsulin in 
i s l e t s of Langerhans _in vitro 
I s le t s of Langerhans were incubated in 1 ml KHB Hagle 's 
14 
medium for 2 hours with 30 uM coleonol and 5 0 uCi C-leucine. 
14 There was a significant increase in the incorporat ion of C-leucine 
into (pro) insu l in when i s l e t s were incubated with coleonol. At 
30 uM coleonol, (16.97±1.3)xl0~ cpm/mg i s let protein C-leucine 
was incorporated into (p ro) insu l in as compared to the control value 
_3 
of (9 .7+0.35)xl0 cpm/mg is le t p ro te in , showing 74.94% percent 
14 increase in the incorporat ion of C-leucine into (p ro) insu l in in 
the presence of coleonol. However, no significant effect on the 
14 incorporat ion of C-leucine into o ther i s le t pro te ins was observed 
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2 0 -
10 
d Control 
| Experimental 
[•] Other Proteins 
> (Pro) insulin 
37: 14 Effect of coleonol on C-Leucine incorpora-
tion into (pro)insulin in islets of Langcrhans 
in vitro. The bars represent the mean 
±S.D. of 6 experiments. 
124 
(Fig. 37). Addition of cycloheximide (10 pg/ml) in the medium 
completely blocked the biosynthesis of (pro)insulin (data not shown). 
Insulin and glucagon secretion jxi vitro 
In can be seen that coleonol is a potent insulin and glucagon 
releaser. At a concentration of coleonol as low as 0.3 uM in the 
medium the glucagon release was 207+13 pg/5 i s le ts /hr as compared 
to control value of 117 + 9.2 pg/5 i s le ts /hr (P< 0.001). Glucagon 
release by coleonol was dose dependent. With 1 uM and 3 uM 
of coleonol the glucagon release was of the order of 417+25.8 and 
503+31.5 pg/5 islets. 'hr respectively (P< 0.001) as compared to 
control (Table 11). 
As shown in Fig. 38 , coleonol had no effect on insulin 
release at 2.8 mM glucose i_n vi tro. However, incubation of coleonol 
with 5.b mM glucose, had significant effect on insulin release. 
Insulin release by coleonol was dose dependent upto 3 uM of its 
concentration. At a concentration of 0.3 ,uM of coleonol, insulin 
release was 80.0±7.1 ;ulu75 islets, hr as compared to the control 
value of 51.2 + 6.2 juIU/5 is le ts /hr (P<0,001). The stimulation of 
insulin release with 1 p\\ and 3 pM was 105.6±10.5 and 144±]f,,3 
uIU/5 is le ts /hr respectively (P<0.001 as compared to control). 
Oral glucose tolerance test and serum glucagon levels in alloxan 
diabetic rats 
Effect of feeding of coleonol on blood glucose level in alloxan 
diabetic rats is shown in Fig. 39 . Intravenous injection of alloxan 
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Table 11 : Effect of 
re lease 
Additions 
Nil 
Coleonol 
varying concent ra t ions 
Concentration 
(pM) 
0.3 
1.0 
3.0 
of coleonol on glucagon 
Glucagon re lease 
(pg /5 i s l e t s / h r ) 
117i9.2 
207±13 
417±25.8 
503±31.8 
Each resul t is exp res sed as the mean of s ix indiv idual e x p e r i -
ments ± S.D. 
150 - T <» 
« > ^ 
' . it 
100 -
50-
i 1—"—r 
2 0 3-0 10 
Cone of coleonol IpM) 
38: Effect of coleonol on in vitro insulin 
release from islets ~~bf Lahgerhans 
in the presence of 2.8 mM (hollow 
circles) and 5.6 mM glucose (bold 
c i rc les) . The bars represent the 
mean t S.D. of 6 experiments. 
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to rats caused about 3.2 fold increase in the blood glucose level 
(P<^0.U01 as compared to normal control). Oral glucose tolerance 
test in alloxan diabetic rats which were fed with coleonol, showed 
a significant increase in blood glucose levels as compared to diabetic 
controls. One hour after feeding of coleonol, the blood glucose 
level in diabetic rats rose from 286±15.5 to 417+17.7 mg/dl while, 
the corresponding blood glucose level in alloxan diabetic control 
rats was 381±21.9 mg/dl, showing 9.4% increase in blood glucose 
level in coleonol treated alloxan diabetic rats as compared to diabetic 
controls (P<U.U2). Feeding of coleonol causes 19.13 percent increase 
in blood glucose level after 2 hrs (P <^ 0.001) and 36.52 percent 
increase in the blood glucose level after 3 hrs (P<0.001) as com-
pared to their respective diabetic controls. 
Feeding of coleonol to alloxan diabetic rats caused a signi-
ficant increase in serum glucagon level. In alloxan diabetic rats 
serum glucagon level was increased to 615±117 pg/ml in coleonol 
fed rats as compared to the control value of 339±26 pg/ml. The 
glucagon level in normal animals was 117±12 pg/ml. (Fig. 40). 
Serum insulin and glucagon levels in normal and coleonol fed rats 
Oral administration of coleonol (10 mg/kg body weight for 
7 days) resulted a significant increase of counter regulatory hormones 
of carbohydrate metabolism I .e . insulin and glucagon in normal 
ra ts . The level of serum insulin was significantly increased to 
20±1.97 ^jIU/ml in coleonol fed rats as compared to the control 
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-o NORMAL 
-• DIABETIC CONTROL 
120 
Time in minutes 
F i g . 39: Effect of colconol on glucose tolerance 
test in a l loxan d iabe t i c r a t s . The 
bars represent mean (± S.D.) of 4 
exper iments . 
*P< 0.001 'as compared to a l loxan d i a -
bet ic con t r o l . 
j
- l ' = N.S. is compared to zero hour 
l e v e l . 
600 -
0 Normal 
H Diabetic Control 
1 Diabetic treated 
615+117 
I 
400 -
en 
a. 200 -
X 
Fig. 40: Effect of coloonol on scrum glucagon lcvol 
in al loxan d iabot ic r a t s . The ba r s roprosonl 
the mean (*S.i : . ) of 4 expe r imen t s . 
iSP<0.001 as compared to normal control . 
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value 14.35±1.17 uILvml (P<0.001) showing 39.37 percent increase 
in serum insulin level. Feeding of coleonol also caused a significant 
increase in serum glucagon level. Serum glucagon level in coleonol 
fed rats was increased to 169±10.9 pg/ml as compared to 112.7 + 7.5 
pg/ml in normal control animals (F<0.001). Thus. feeding of coleonol 
caused a 50 percent increase in serum glucagon level and the increase 
in serum glucagon level was much greater than the increase in sinulin 
level in coleonol fed rats . (Table 12). 
Blood glucose and serum free-fatty acid levels in normal and coleonol 
fed rats 
Feeding of coleonol (10 mg/kg body weight for 7 days) 
caused a significant increase in the blood glucose and serum free 
fatty acid levels. The level of blood glucose 70.3±3.5 mg/dl was 
increased to 84.1 + 3.9 mg/dl in coleonol fed rats (P< 0.001. 19.6% 
increase in blood glucose as compared to control). The level of 
free fatty acids (a substrate for gluconeogenesis) was also increased 
from 0.051 + 0.003 mmole/lit to 0.079±0.005 mmole/lit in coleonol 
fed rats as compared to control (P<0.001). (Table 12). 
Liver glycogen level and glucose-6-phosphatase activity _in vivo 
Coleonol feeding to rats (10 mg/kg body weight for 7 days) 
caused a significant increase in liver glucose-6-phosphatase act ivi ty, 
with depleting liver glycogen. The activity of glucose-6-phosphatase 
was increased from 7.25i0.035 Inits/gm liver in normal rats to 
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Table 12: Blood glucose, serum insulin, glucagon and free-fatty 
acid levels in normal and coleonol fed rats 
Parameters Control Experimental 
Blood glucose 70.3±3.5 84.U3.9 
(mg/dl) 
Serum insulin 14,35±1.17 20.0±1.97 
Serum glucagon 112.7+7.5 169.0±10.9 
(pg/ml) 
Free-fatty acid 0.051±0.003 0.079±0.005 
(mmole/lit) 
Results are expressed as mean ± S.D. for 6 different observations. 
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10.96+.0.056 Units/gm liver in coleonol fed rats (P< 0.001), while 
glycogen level in normal rat liver was decreased from a control 
value of 43.25*3.45 mg/gm to 25.56 + 3.78 mg/gm in coleonol fed 
rats showing 40.90% decrease (P<0.001). (Table 13). 
Effect of coleonol on the activities of cathepsin B and acid phos-
phatase in islets of Langerhans _in vivo 
Oral administration of coleonol in rats (10 mg/kg body 
weight for 7 days) caused a significant stimulation in the activities 
of cathepsin B and acid phosphata.-<,' in islets of Langerhans. Table 
14 shows that cathepsin B activity was stimulated to 0.93±0.14 as 
compared to 0.16±0.O2 pinoles tyrosine released/mg protein/min in 
the case of control animals showing 5.81 fold increase (P<0.001). 
There was also a significant stimulation of acid phosphatase activity 
in coleonol fed animals. Acid phosphatase activity was raised 
from 7.12±0.23 nmoles of p-nitrophenol formed/mg Protein/minute 
to 12.25+0.47 showing 72% increase in enzyme activity (P <0.001). 
Oxygen uptake studies in normal and coleonol fed rats liver mito-
chondria _in vivo 
Liver mitochondria were isolated from normal and coleonol 
fed ra ts . Oxygen uptake studies were carried out by incubating 
mitochondria in oxygraph's vessel in Hank's medium at 30°C. Oxygen 
uptake increased significantly in the liver mitochondria of coleonol 
fed rats as compared to normal rat l iver mitochondria. Oxygen 
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Table 13: Liver glycogen level ami glucose-6-phosphatase activity 
in normal and coleonol fed rats 
Parameters Control Experimental 
Glycogen 43.25±3.45 25.56±3.7[ 
(mg/gm) 
Glucose-6-phosphatase 7.25±0.035 10.96+0.056 
(units/gm) 
Each result is expressed as mean of 5 individual experiments±S. D. 
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Table 14: Effect of coleonol on cathepsin B and acid phosphatase 
activity in islets of Langerhans in vivo 
Enzyme Control Experimental 
Cathepsin B'" 0.16±0.02 0.93±0.14 + 
Acid phosphatase"" 7.12±0.23 12.25±0.47+ 
Results are expressed as mean ± S.D. for six different observations 
+P(0.001 
jjmoles of tyrosine liberated/mg protein/min 
.'. •>. 
... .,. 
nmoles of p-nitrophenol formed/mg protein/min 
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uptake increased from 22.53*1.51 ul of 0„ consumed/mg protein/hr 
to 33.93+.3.20 ,ul of Cu consumed/mg protein/hr showing 50.6% increase 
in LL uptake in coleonol fed rats at 2.8 mM glucose concentration 
in the medium. In the same way, when glucose concentration was 
increased to 16.7 m.M in the incubaiion vessels, there was a further 
increase in 0„ uptake in both coleonol fed rats as well as normal 
rat liver mitochondria. LL uptake in the liver mitochondria of 
coleonol fed rats at 16.7 mM glucose concentration was increased 
to 48.0+5.4 ul C> consumed/mg protein/hr as compared to the control 
value of 31.27+2.3 (P<0.001) showing increased utilization of glucose 
in coleonol fed rats (Table 15). 
Effect of synthetic analogues of C-termlnal tetrapeptide amide of 
cholecystokinin (CCK-4) on insulin release from islets of Langerhans 
in vitro 
The effect of CCK-4 and the following four synthetic ana-
logues were studied on i_n vitro insulin release from the is le ts . 
CCK-4: Trp-Met-Asp-Phe-NH2 
Peptide iv: Pro-Met-Asp-Phe-NPL 
v: Thz-Met-Asp-Phe-NH2 
vi: APro-Met-Asp-Phe-NH2 
vii: L-Pro-Met-Asp-Phe-NH2 
The results are presented in Figs. 41,42 The peptides were 
incubated with islets of Langerhans at concentrations ranging from 
10 M to 10 M in the incubation medium containing 2 or 20 mM 
glucose. 
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Table 15 : Effect of coleonol on oxygen uptake in rat liver mito-
chondria 
Concentration of Oxygen uptake 
glucose ;jl CWmg protein/hr 
(m.M) 
Control Experimental 
2.8 22.53tl.51 33.93±3.20 
16.7 31.27±2.3 48.00±5.4 
Results are expressed as the mean ± S.D. for 6 different obser-
vations. 
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(i) With 2 mM glucose: Results presented here confirm that CCK-4 
-10 is a potent releaser of insulin. At as low concentration as 10 M, 
CCK-4 stimulated the release of insulin in the order of 72±8 uIU/5 
i s le t s /h r , (89.5% increase over control, P< 0.001). The release 
of insulin from the islets by CCK-4 was dose dependent. Thus, 
the release with 10 M and 10 M concentration of CCK-4 was 98±7.5 
yUlU/5 is le ts /hr (36.11% increase compared to 10"10M, P<0.001) and 
_ Q 
148±9.4 plll/o i s le ts /hr (51% increaso compared to 10" M) respectively. 
Insulin release from the islets of Langerhans under the 
influence of peptides iv, v, vi are shown in Figs.41 ; respectively. 
The results confirm that these peptides are potent releasers of 
insulin. Peptide IV (D. Pro subsituted at position I) is more 
potent insulin releaser compared to its parent molecule, CCK-4. 
-10 At 10 M concentration of peptide IV, the insulin release was 77.5±6.2 
p.IU/5 i s le t s /hr (104% increase over control, P ^0 .001) . The stimula-
_ o _ c 
tion was dose dependent. The insulin release with 10" and 10~ M 
concentrations of the peptide IV was 108±7.1 uIU/5 i s le t s /hr (39.4% 
-10 increase compared to 10 M, P<0.001) and 167+8.3 / J I U / 5 i s le t s /hr 
(54.62% increase compared to 10" M of the peptide, P<0.001). 
Peptide numbers V and VI also stimulated the release of 
insulin but it was less pronounced compared to that with CCK-4 
and peptide IV. Peptide V was more effective as a releaser of 
— 10 — R 
insulin than peptide VI. The insulin release with 10~ M, 10~ 
— R 
and 10 M concentrations of peptide V was 54±3.7 JJIU/5 i s le ts /hr 
(42% more over control, P < 0.001), 91±5.3 ,uIU/5 i s le t s /h r (68.5% 
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more compared to 1 0 , P<0.001) and 129+7.2 J I IU/5 i s le t s /hr (41.7% 
more compared to 10~ M, P< 0.001). Thus, at the concentration 
—fi 
of 10~ M of the peptide, stimulation of insulin release by peptide 
TV was 22'. 7500 more than that with CCK-4. No stimulation of insulin 
release uy peptide VI was observer!' "at 10" M concentration. However, 
_ o _ c 
at 10 and 10 M concentrations of th is peptide, insul in release 
was 45±3.1' nil' 5 islets hr (18.42% more were control, P<0.001)and 
69±5.6 ^uIU/5 is le ts /hr (53.33% more compared to 10~%resp3Ctively(Fig.41). 
( i i i) With 20 mM glucose: The effect of CCK-4 and its three 
synthetic congeners (Peptides iv , v and vi) were studied for their 
insulin releasing activity from islets of Langerhans in the presence 
of 20 mM glucose in the incubation medium. Cholecystokinin and 
i ts analogues were found to have an additive effect on the release 
-10 
of insulin over that with glucose alone. At 10 M of CCK-4 concent-
ration ITT the incubation medium, insulin release was stimulated 
to 97.5±4.5 plU/5 i s le t s /h r (35.4nu more over control) significantly 
higher than that obtained with glucose (20 mM) alone (72±5.6 pIU/5 
—ft —fi 
i s l e t s / h r ) . With 20 mM glucose and 10~ and 10~ M concentrations 
of CCK-4, insulin release was 148.9+8.3 juIU/5 i s le t s /hr (52.7% more 
-10 
compared to 10 M ) and 217±7.3 u IU/5 i s le t s /h r respectively 
_ o 
(45.7% more compared to 10" M, P< 0.001). Insulin release, at 
ft fi 
10 and 10 M concentrations of CCK-4 was 98±7.5 and 148±9.4 
uIU/5 i s le ts /hr respectively at 2 mM glucose concentration in the 
medium. Likewise, synthetic analogues of CCK-4 also show increased 
stimulation of insulin release over that with glucose alone. Thus, 
in the presence of 20 mM glucose and 10" M concentration of peptide 
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iv, insulin release was stimulated to 106±5.3 juIU/5 i s le t s /hr (47.22% 
increase over control, P<0.001). With 20 mM glucose, the Stimula-
te _ c 
tion of insulin release at 10 and 10" M concentrations of peptide 
IV was 161 + 6.0 and 249±8.3 ^iIU/5 i s le ts /hr respectively, compared 
to 108±7.1 and 167+8.3 ,uIU/5 is le ts /hr with 2 mM glucose. Peptide 
IV stimulated more insulin release from islets of Langerhans compared 
to CCK-4 both at stimulatory and non-stimulatory concentrations 
of glucose. (Fig. 41.42). 
Peptide V was found to stimulate insulin release upto a 
dilution of 10 M with 20 mM glucose in the medium, and at 
the same glucose concentration, peptide VI stimulated insulin release 
- H — ft 
upto the dilution of 10 M. At 10 M concentration of the peptides 
V and VI, the release of insulin was 135±3.9 and 91±3.7 yUlU/5 i s le ts /hr 
respectively. (Fig. 42). 
For comparison, the data of the insulin release in response 
to CCK-4 and its analogues at various concentrations is depicted 
in the figures. (Fig. 41,42). 
Effect of synthetic analogues of C-terminal tetrapeptide amide of 
cholecystokinin (CCK-4) on glucagon release from islets of Langerhans 
in vitro 
The effect of CCK-4 and its four synthetic analogues IV, 
V and VI mentioned earl ier (page 135) were tested for their glucagon 
releasing activity from islets _i_n vitro in the presence of 2 and 
20 mM glucose in the medium. 
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(i) Glucagon release in the presence of 2 mM glucose: Results 
presented, confirmed that CCK-4 is a potent releaser of glucagon 
-10 from islets of Langerhans upto a concentration of 10 M when the 
-10 
glucose concentration in the medium was 2 mM. At 10 M concentra-
tion of CCK-4, the glucagon release was 160±10.4 pg/5 i s le ts /hr 
as compared to the control value of 115+8.9 pg/5 i s le ts /hr (39.13% 
increase over control, P< 0.001). The CCK-4 stimulated glucagon 
release was dose-dependent and increased with the concentration 
- f t 
of peptide. Thus, the glucagon release from islets at 10 and 
10_" M CCK-4 concentrations was 225±12.8 pg/5 i s le ts /hr (40.62% 
increase compared to 10 M, ?< 0.005) and 430±27.2 pg/5 Is le ts /hr 
—ft (91.1% increase compared to 10~ M, P<0.001) respectively. (Fig.43). 
CCK-4 analogues, numbering IV, V and VI which have sub-
stitutions at position 1, in place of Trp. with (D-Pro, Thiazolidino-
4-carboxylic acid and ^Pro) showed no effect on the release of 
glucagon even upto a concentration of 10 M. (Fig. 43). 
(i i) Glucagon release in the presence of 20 mM glucose: CCK-4 
and its synthetic analogues were tested _in vitro for their glucagon 
releasing activity from isolated islets of Langerhans in the presence 
of 20 mM glucose. The results have been presented in Fig. ^4 
Glucagon release at 20 mM glucose concentration in the 
-10 
medium was 79±8.6 pg/o i s le ts /hr in response to 10 M CCK-4, 
whereas the control value (without CCK-4) being 65±4.6 pg/5 i s le t s /h r . 
Glucagon release in the presence of 2 mM glucose was 115±8.9 pg/5 
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is le ts /hr (control vnluo) which Is significantly groator than tho 
glucagon release at 20 mM glucose (P<0.001). At 10~10M CCK-4, 
increase of glucose concentration to 20 mM resulted in 50.62% inhibi-
tion of glucagon release compared to 2 mM glucose. At the same 
— R 
glucose concentration and lower dilutions of CCK-4, i . e . 10 and 
10 M, the glucagon release was 107+6.5 pg/5 i s le ts /hr (P<0.001, 
compared to control) and 187+10.9 pg/5 i s le ts /hr (P^O.001, compared 
to 10"8M CCK-4) showing inhibition of 52.4 and 56.5% respectively 
with respect to that with CCK-4 and 2 mM glucose. 
Synthetic analogues of CCk-4 (Peptides IV, V and VI) had 
no significant effect on the release of glucagon from the islets 
in the presence of 2 mM glucose concentration, while with 20mM 
glucose concentration, the release of glucagon was inhibited by 
peptides IV and V. Peptide VI had no significaht effect on tho 
release of glucagon from islets even at 20 mM glucbse concentration 
in the medium. As can be seen in Fig.4^ , Peptide IV significantly 
_ Q 
inhibited glucagon release upto its 10 M dilution, while peptide 
V inhibited the release of glucagon only upto 10~ M of its dilution. 
With 20 mM glucose and 10" and 10" M concentrations of peptide 
IV, glucagon release was inhibited to 59±2.3 pg/5 is le ts /hr 
(P<0.01 as compared to control) and 45+3.5 pg/5 i s le ts /hr (P<0.001 
as compared to control) showing 9.2 and 30.8 percent inhibition 
of glucagon release respectively. At 10" M, peptide V inhibited 
glucagon release to 53±2.5 pg/5 i s le ts /hr (P<0 .01 , as compared 
to control) showing 18.46% inhibition in glucagon release. 
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Effect of age on peptide (CCK-4, DPMAP, LPMAP) stimulated insulin 
release from islets of Langerhans In vitro 
Insulin release jln vitro from the islets of Langerhans of 
1 and 12 months old rats in response to 10 M concentrations of 
CCK-4, DPMAP (Peptide IV), LPMAP (Peptide VII) are shown in 
Figs. 45 . With 2 mM glucose concentration in the medium, CCK-4 
and its analogues (DPMAP and LPMAP) stimulated the release of 
insulin quite significantly. Howevor, insulin release in response 
to CCK-4 and its analogues tested here decreased with the advance-
ment of animal's age. Thus, while the insulin release at 10" M 
concentration of CCK-4 from the islets of 1 month old rats was 
148±9.4 uIU/5 i s le ts /hr (3.89 fold increase over the control). 
The release of insulin in the case of 12 months old rats in response 
to CCK-4 was only 107±(iJ juIU/5 i s le t s /hr , control value being 38±4 
/jIU/islets/hr (2.82 fold increase). It would appear that CCK-4 
induces a 1.38 fold increase in insulin release in islets from 1 
month old rat as compared to that of 12 months old ra t s . Likewise, 
DPMAP (Peptide IV) a synthetic analogue of CCK-4, more effectively 
stimulates insulin release as compared to CCK-4. Insulin release 
at 10" M concentration of DPMAP; from 12 months old rats was 
117+6.7 uIU/5 i s le ts /hr as compared to 167±8.3 /jIU/5 i s le ts /hr in 
the case of 1 month old ra t s . Thus, there was 1.42 fold more 
release of insulin from islets of 1 month old rats compared to 
12 month old ones. LPMAP, (Peptide VII) being less effective 
stimulator of insulin release compared to CCK-4 and DPMAP. LPMAP, 
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released only 97±5.2 jaIU/5 is le ts /hr insulin in 12 months old rats 
as compared to 137±G. 7 ;iIU/fi ls lots /hr Insulin In tho cnsn of onn 
month old ra t s , showing 1.41 fold increase in insulin release in 
the case of islets from 1 month old rats as compared to that of 
12 months old. 
D I S C U S S I O N 
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Insulin like activity in (-)epicatechin 
The results presented here clearly demonstrate that (-)epica-
techin mimics insulin, when tested on different target tissues in 
14 
vitro. (-)Epicatechin causes an increased incorporation of U -C 
glucose into glycogen of rat diaphragm and increases glycogen content 
— in vi t ro . It stimulates glucose metabolism as evident from the 
increased CL-uptake in fat cells, muscle and l iver t issues. Since 
uptake and uso of glucose in brnin Is inclopondont of Insulin, thorn 
is no effect of epicatechin too on 0„-uptake in brain. Stimulation 
of electron transport chain by epicatechin leading to increased 
CL-uptake is completely inhibited by sodium-azide. Epicatechin 
also stimulates phosphofructokinase and inhibits glucose-6-phospha-
tase activity of the islets _in vi tro. 
The hypoglycemic effect of (-)epicatechin, has been reported 
by Chakrawarthy et al . (1980, 1901). Those authors have shown 
that (-)epicatechin, injected intraperitoneally into alloxan diabetic 
rats brings about normalization of blood glucose level and helps 
B-cells regeneration. When injected into normal rats for four days 
prior to alloxan injection, epicatechin protects the islets from 
the toxic effect of alloxan. Charles et^  al_. (1984) have shown 
that (-)epicatechin has direct effect on islets of Langerhans and 
increases insulin secretion during short term static incubations 
and in perifusion. The effect was ATP, temperature and dose 
dependent. J_n vitro stimulation of DNA synthesis by (-)epicatechin 
has also boon demonstrated. 
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The evidences gathered in present studies (data not presented) 
do not support the finding of Chakrawarthy et^  al_. (1981) that 
(-)epicatechin help regeneration of B-cells. However, (-)epicatechin 
appears to compare well with insulin in its biologic act ivi t ies . 
These insulin like activities of (-)epicatechin may be either due 
to its enhancing effect on the binding of insulin to its receptor 
or, may be, due to its own binding on some receptor on the target 
cell membranes. The nature of the receptor, if any, for epica-
techin has not been investigated in the present studies. However, 
possibility of such binding exists. It was of interest, therefore, 
to see whether epicatechin shares a common binding site with 
insulin or not. Competitive binding experiments between (-)epica-
125 techin and I-insulin suggest that the binding site if any, for 
(-)epicatechin is different from that of insulin. Effect of (-)epica-
techin on some post binding steps of insulin action also cannot 
be ruled out. A receptor, different from that of insulin if present 
on B-cell, may prove to be valuable tool for the control of hyper-
glycemia; providing an alternative binding site in the cases whoro 
there is a lack of insulin receptor on the target tissue. Thus, 
in (-)epicatechin, we find dual biologic activity. On the one hand, 
it shows biologic effects comparable to that of insulin and on 
the other, it acts as an insulinogenic agent and has no effect on 
glucagon release from the is le ts . 
Effect of age on (-)epica techin stimulated insulin release from 
islets in vitro 
Our results show that there is a correlation between 
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(-)epicatechin stimulated cAMP content in islets of Langerhans 
and insulin release. Stimulation of insulin release from the islets 
of~~ Langerhans by (-)epicatechin is dose dependent and corresponds 
with the increase in the cAMP content of the is le ts . Reports 
on the effect of insulinogogues on the cAMP content of the islets 
have been contradictory. Rabinovitch et a l . (1978b) and Malaisse 
et a l . (1984) have reported that there is an increase in the cAMP 
content of the islets during glucose stimulated insulin release. 
Contradictory to these findings Ullrich and Wollheim (1984) could 
not find any change in the islets cAMP content with glucose stimu-
lation. Our findings that exposure of islets in vitro with (-)epica-
techin at different concentrations of glucose does increase the cAMP 
content of the islets support the findings of Rabinovitch e^ al_. 
(1978) and Malaisse et_ al. (1984). 
The effect of (-)epicatechin on insulin release at 2 and 
20 mM glucose concentrations have been demonstrated by Charles 
et al . (1984) in static incubations as well as in porlfuslon. III! 
et al . (1985) have reported its effect on the release of insulin 
45 + + 
and uptake of Ca in isolated islets of Langerhans of ra ts . 
The data presented here show that with optimal glucose concentration 
(20 mM) in the medium, (-)epicatechin st i l l increases the cAMP 
content of the islets dose dependently, showing independent effect 
of (-)epicatechin stimulated increase in the cAMP content of the 
i s le ts . Glucose and epicatechin are known to raise intracellular 
Ca + concentration in islets (Hii 8 Howell, 1984, Charles et al. ,1975), 
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which may be responsible for the increase in tho cAMP content. 
Whether (-)epicatechin itself raise the Ca concentration of the 
cell or it acts through potentiation of glucose activity for increasing 
the intracellular Ca has not been shown in the present studies. 
(-)Epicatechin may prove to be good hypoglycemic agent since 
it has no effect on the release of glucagon from islets at 
2 mM glucose concentration in the medium. 
When the effect of age on the (-)epicatechin stimulated 
insulin release and the corresponding cAMP content of the islets 
was investigated, it was found that the younger rats respond well 
both with respect to (-)epicatechin stimulated insulin release and 
the (-)epicatechin stimulated increase in cAMP content of is le ts . 
With the increasing age of the animal there was sharp decline 
in the islets response to the (-)epicatechin stimulated insulin 
release as well as on the increase in the cAMP content. This corres-
ponds to age related decrease in (-)epicatechin stimulated insulin 
release both at 20 mM and 2 mM glucose concentration despite 
the fact that size of is le ts , number of B-cells per islet and number 
of secretory granules per B-cells increase with increasing age 
of _the animal. From the results presented here, it appears that 
basal insulin release at 2 mM glucose does not alter significantly 
with the age of the animal. This is in agreement with tV.e findings 
of Lipson et aL (1981a). However, (-)epicatechin, stimulates 
insulin release even at 2 mM glucose concentration. However, epica-
techin stimulated insulin release is decreased significantly as the 
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age of the animal increases. In view of these findings it may 
be concluded that (-)epicatechin stimulated insulin release of the 
45 + + islet is due to increase of cAMP content and increased Ca uptake. 
The correlation between the epicatechin concentration dependent 
increase of islets cAMP content and stimulation of insulin release 
presented here implies that the increase of cAMP content is a 
pre-requisite for the stimulation of insulin release. 
The effect of (-)epicatechin on the conversion of proinsulin 
to insulin have also been determined by the measure of the content 
of proinsulin and insulin after incubation for 2 h r s . Results presented 
- show that conversion of proinsulin to insulin is more pronounced 
in 1 month old rats as compared to 12 months. There is 9.4% 
more decrease of proinsulin in 1 month old rats as compared to 
12 months. Percent decrease of proinsulin was 35.4% in one month 
old rats as compared to 26% in 12 months old ra ts . As has been 
shown earl ier , cathepsin B of pancreatic islets is stimulated in 
the presence of insulin secretagogues. Cathepsin B in islets has 
been implicated in the conversion of proinsulin to insulin by many 
workers (Bansal e£ al_. , 1980; Puri et_ al_. , 1978; Ansorge et_ al. , 
1977). Our results show that there is a corresponding increase 
in the cathepsin B activity in islets with the conversion of pro-
insulin to insulin. The exact mechanism of how cathepsin B may be 
involved in the transformation of proinsulin i s , however, not clear. 
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Aging may be one of the factors responsible for the confi-
gurational changes in B-cell membrane and the arrangement of the 
membrane compartments affecting the binding of insulin secretagogues 
to the membrane. This might be responsible for the decrease 
in the response of B-cells towards the glucose and (-)epicatechin 
stimulated insulin release and conversion of proinsulin to insulin 
in older animals. 
Insulin and glucagon releasing activity of coleonol, and its effect 
on blood glucose level in normal and alloxan diabetic rats 
The present studies show that the release of insulin and 
glucagon from the isolated islets is enhanced by coleonol when 
the islets are incubated with it in vitro and also when it is fed 
orally. Working on forskolin, (a diterpenoid isolated independently 
by other workers from the same source), similar results have 
been obtained by Wiedenkeller et_ al_. (1983) in their experiments 
on isolated rat islets and by Hermansen (1985) on isolated perfused 
dog pancreas. Our results , besides confirming the hormone releasing 
property of the coleonol in vitro, also show that this diterpenoid 
is an effective releaser of both the hormones after its oral feeding. 
Coleonol does not release insulin from the islets in vitro, when 
the concentration of glucose in the medium is not stimulatory (2.8 
mM). However, it stimulates glucagon release significantly and 
dose dependently from is le ts . However, when the glucose in the 
medium is raised to the stimulatory concentration of 5.6 mM, there 
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is a pronounced enhancement in the release of insulin. Thus, 
coleonol seems to be a good potentiator for the release of insulin. 
The potentiation of the glucose stimulus for the release of insulin, 
by coleonol is dose-dependent upto 3 uM concentration in the medium 
and any further increase in the coleonol concentration has no effect 
on the release of insulin from islets of Langerhans. Stimulation 
of proinsulin biosynthesis by coleonol has been demonstrated in 
14 the present studies by studying the C-leucine incorporation into 
proinsulin. Working on forskolin, Wiedenkeller ei_ a]_. (1983) have 
shown that it causes a concentration dependent formation of islets 
cAMP which in turn increases the biosynthesis of proinsulin (Trevor 
14 6 Taylor, 1986). Thus, stimulation of C-leucine incorporation 
into proinsulin as shown in the present studies may be the result 
of the sequence of events, starting from the increased formation 
of cAMP and leading to the stimulation of proinsulin biosynthesis. 
It is interesting to note that at the nonstimulatory glucose concent-
ration, the diterpenoid increases cAMP level in the islets 
(Wiedenkeller et_ ah , 1983) but without any effect on the release 
of insulin. This indicates that cAMP may not be an initiator for 
the release of insulin. 
Feeding of coleonol to rats results in a significant increase 
in the level of serum insulin and glucagon. However, the release 
of glucagon compared to that of insulin is significantly more indicat-
ing greater response of A-cells to coleonol than of B-cells. This 
explains the observed hyperglycemic effect of the oral feeding 
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of coleonol to rat, presented in this dissertation. The hyper-
glycemic effect of oral feeding of coleonol has been more clearly 
demonstrated by feeding coleonol to alloxan diabetic ra t s . The 
hyperglycemia caused by coloonnl in alloxan diabetic rats after 
coleonol feeding is much more pronounced than in the alloxan diabetic 
rats without coleonol feeding. Other parameters, like serum free 
fatty acid level, glucose-6-phosphatase act ivi ty, liver glycogen 
content and the 0 ?-uptake in the isolated liver mitochondria after 
7 days feeding of coleonol show development of diabetic symptoms 
probably due to predominant release of glucagon. 
Effect of synthetic analogues of C-terminal tetrapeptide amide of 
cholecystokinin on insulin and glucagon release in vitro 
The C-terminal tetrapeptide amide (CCK-4), which is common 
to cholecystokinin and gastrin, has gained an added importance 
after it was detected in the CCK nerve terminals of the pancreas 
by Rehfeld et^  al_. (1980). These authors suggested that CCK-4 
might be involved in the regulation of islet cell functions and 
showed that it stimulates the release of all four islet hormones. 
The studies on structure-activity relationship of different molecular 
forms of CCK-4 ware undertaken by us. with the view to obtaining 
analogues with effects similar to those of glucose, a natural physio-
logic factor in the regulation of islet hormone secretion. 
Rehfeld el_ a_l_. (1980) working on structure activity relation-
ship of CCK-4 have shown that C-terminal modification of this 
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molecule r e s u l t s in considerable loss of i t s a b i l i t y to s t imulate 
the r e l e a s e of insul in , glucagon and o the r i s l e t hormones. Ear l ie r 
s tud ies from th i s labora tory have demonstrated that methylation 
of the C-terminal res idue of the above t e t r a p e p t i d e r ende r s the 
CCK-4 analogue (Pep t ide I) inh ib i to ry to the r e l ea se of both insulin 
and glucagon in a dose dependent manner (Khalid et_ a h , 1989). 
It has a lso been repor ted by our group that modification at posit ion 
2 of t h i s analogue by subst i tut ing Met with Ser (Pep t ide II) does 
not have much effect on the nature of i t s a c t i v i t i e s except that 
the new congener is markedly more i nh ib i t o ry to insulin re lease 
than to glucagon re lease (Khalid a[ a l . , 1909). Uohfeld e_t^  ah 
(1980) on the bas i s of h i s s tud ie s has concluded that free Trp 
at posi t ion one and -Phe-NH„ terminii a r e necessary for i t s socrc ta -
gogue a c t i v i t y . Contradictory to these f indings, Nafees et a l . 
(1984) from th i s laboratory have r epor t ed that replacement of 
Trp by Pro at posi t ion 1 re ta ins the insulin re leas ing ac t i v i t y 
of the analogue, however , i t completely loses i t s glucagon re leas ing 
a c t i v i t y . Methylation of C-terminal amide of th i s analogue y ie lds 
an in te res t ing analogue (Pept ide I I I ) , whi le retaining the insulin 
re leas ing a c t i v i t y , t he new analogue becomes i n h i b i t o r y to the 
r e l e a s e of glucagon, both effects being dose-dependent (Khalid 
et^  _al_. , 1989). The present s tud ies a re in continuation of the above 
s t r u c t u r e a c t i v i t y re la t ionsh ip s tud i e s i n i t i a t ed in t h i s l a b o r a t o r y . 
The r e s u l t s p resen ted here demonstrate that replacement of Trp 
with D-Pro in CCK-4 molecule y i e l d s analogue which has a potent 
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insulin re leas ing a c t i v i t y comparable to that of the parent molecule, 
CCk-4. While th i s analogue r e l eases insulin in a dose-dependent 
manner, it has no effect on the r e l ease of glucagon. 
Likewise int roduct ion of o ther s tereoisomers of prol ine (D-
Pro , L-Pro , or Thz -4 -ca rboxy l i c ac id) at posi t ion 1 in place of 
Trp does not effect much the insulin re leas ing ac t i v i t y of the 
analogue but • abo l i shes the glucagon re leas ing a c t i v i t y in all the 
analogues. Our r e su l t s suppor t the findings of Nafees ot_ aj_. (11)84), 
that Trp or the aromatic nature of amino acid at posi t ion 1, has 
nothing to do with the biologic a c t i v i t y of the anloguc and its 
a c t i v i t y is not s ignif icant ly lost when a cyc l ic amino acid Pro 
or i t s s te roo isomer ic form takes the place of Trp at the position 
one of the t e t r a p e p t i d e , CCk-4. Our r e su l t s also show that pep t ide 
IV, V and VI (D-Pro , Thz and ^ P r o at 1st posi t ion) have add i t i ve 
effect on the glucose st imulat ion of insulin r e l e a s e . Thus, the 
insulin re leas ing a c t i v i t y with increasing concentrat ion of glucose 
is enhanced when these CCK-4 analogues a re present in the medium. 
The analogue having Thz at posi t ion one (Pep t ide V) is less ac t ive 
than the one having L-isomer of pro l ine (Pep t i de VII) and the 
analogue having Pro (Pep t ide VI) has the lowest insulin re leas ing 
a c t i v i t y among the t h r e e . When Trp was rep laced by aromatic 
amino ac ids (Phe , T y r ) , t h e r e was complete loss of insulin and 
glucagon re leas ing a c t i v i t y of CCK-4. At subopt imal glucose con-
centra t ion (2 mM) in the medium, the pep t i de s IV, V, VI do not 
affect the r e l ea se of glucagon from the i s e l t s . However, when the 
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glucose concentration is ra ised to 20 mM, the re is significant i nh i -
bi t ion of glucagon re lease by pep t ide IV and V at 10 M concentrat ion 
Pep t ide VI has no inh ib i to ry effect on the re lease of glucagon 
at both the glucose concentrations in the medium. CCK-4 as such 
is a ve ry potent r e l ease r of insulin and glucagon at concentration 
of glucose (2 and 20 mM) in the medium. 
Insulin r e l ease in v i t ro from the i s l e t s with non s t imula tory 
glucose concentrat ion of 2 mM in the medium remains constant i r r e s -
pec t ive of the ago of the animal as has boon shown in the present 
s tud ie s with i s l e t s from 1 and 12 month old r a t s . Keeping the 
non s t imula tory glucose concentrat ion constant , if CCK-4 or its 
analogue on which Trp has been rep laced at posi t ion one by I'm 
are added to the medium, the re is a s h a r p increase in the r e l ease 
of insul in . This response of i s l e t s towards CCK-4 s t imulat ion 
of insulin r e l ea se seems to be r e l a t ed to the age of the animal. 
In younger animals , there is much more s t imulat ion of CCk-4 s t imu-
lated insulin r e l ease compared to the i s l e t s from the 12 month 
old r a t s . 
It has been shown by Verspohl et_ a]_. (1988) that cho lecys to -
kinin effects insulin re lease through st imulat ion of CCK r e c e p t o r s . 
Whether the r e l ea se of glucagon is mediated by the same recep to r 
sub type and whether the obse rved different effects of CCK-4 d e r i -
va t i ve s on insul in and glucagon r e l e a s e a re r e l a t ed to different 
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affinities for the receptors of CCK-4 analoeues are open questions. 
The possible usefulness of these CCK-4 analogues in the treatment 
of type II diabetes mellitus can only be ascertained after further 
in vivo studies. 
S U M M A R Y 
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The endocrine pancreas exe r t s i t s key metabolic functions 
through a complex in te rac t ive endocrine un i t s , d i s p e r s e d over 
the e n t i r e pancreas . In sea rch for the mechanism and factors 
r e spons ib l e for normal and abnormal glucose homeostas is , pancreat ic 
un i t s , i s l e t s of Langerhans have been the subject of s t u d y . At 
least four different i s le t ce l l s have been d i s t i ngu i shed , all of 
which e x h i b i t the features of sec re to ry c e l l s . The hormones, 
insul in , glucagon and somatostatin have been identif ied r e s p e c t i v e l y 
in 13, A and I) c e l l s . llomeostatic regulation of metabolic fuels 
involves intricate; balance in the secre t ion of islet hormones. Pot-
en t ia l ly important regulatory factors for the sec re to ry ac t iv i ty 
of is let ce l l s appea r highly dependent on var ious nu t r i en t s , hor -
mones, neu ro t r ansmi t t e r s , s u b s t r a t e s and in t r ins ic response oi the 
l i ve r (hepa t i c glucose autorogulut ion) . 
Fac tors which govern the in t race l lu la r events in the endo-
cr ine pancreas remain poorly defined, l ike o the r t i s sues , is le t mem-
brane regula te a lso cycl ic AMP l e v e l s , which modulate B-cell funct-
ion. In a d d i t i o n , B-cell is equipped with g lucoreceptor , nature 
and loca l iza t ion of which is s t i l l con t rove r s i a l . The glucose recog-
nit ion r e p r e s e n t s an important physiologica l event for the B-ce l l , 
c ruc ia l for the insul inot ropic effect of o ther agents and capable 
of inducing hormone s y n t h e s i s , t r anspor t and r e l e a s e . Impairment 
in the s e c r e t o r y response of the B-cell a p p e a r s a c h a r a c t e r i s t i c 
feature of matur i ty onset d i a b e t e s . 
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Insulin is an anabolic hormone and coordinates the action 
of o the r hormones which a re involved in in te rmedia ry metabolism 
such as t h y r o x i n e , growth hormone, glucagon, g lucocor t i co ids , in-
volved in the ut i l izat ion of food, thermogenesis and t i ssue main-
tenance. Insulin acts by binding to i t s target t i ssues and has 
s t imula tory effect on glucose oxidat ion in target t i s s u e s . Insulin 
ac t iva t e s the syn the s i s of glycogen, l i p i d , p ro t e in s , nucleic a c i d s , 
within the c e l l s . 
In the present s tud ies ( - Jop ica toeh in was tested for i ts 
insulin l ike effects on target t i ssues in v i t r o . Nature; of the binding 
s i t e of (- )epica techin on target ce l l s have been s tudied by com-
pe t i t i ve binding with I - insu l in . Kilorts have also been made 
to gain some knowledge about the effect of age on the; i s l e t s isolated 
from different age group of r a t s in response to ce r ta in insulin 
secre tagogues . Studies on the conversion of proinsul in to insulin 
and ca theps in B a c t i v i t y in i s l e t s of Langerhans have a lso been 
ca r r i ed out . Coleonol, a d i t e rpeno id , i so la ted from Coleus forskohl i i 
was s tud ied for i t s effect on blood glucose, serum free fatty acid 
level as well as on l i v e r g lucose -6 -phospha tase a c t i v i t y and glycogen 
leve l af ter ora l feeding. In add i t i on , insu l ino t ropic action of cho le -
cys tokin in and i t s syn the t i c congeners were s tud ied at s t imula tory 
and non-s t imula tory concentrat ions of glucose a re p resen ted in t h i s 
d i s s e r t a t i o n . 
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I. Insulin l ike ac t iv i ty in ( - )cpicatechin 
( i ) Effect of ( - )epicatechin on oxygen uptake in t issues and fat 
c e l l s in vi tro 
At one mill imolar concentration of ( - ) ep i ca t ech in , oxygen 
uptake increases s ignif icant ly in fat c e l l s , l i v e r , hea r t but not 
in bra in t i s s u e s . The st imulation of oxygen uptake in different 
t i s sues and ce l l s was blocked by sodium az ide . 
14 ( i i ) Effect of ( - )epicatechin on incorporation of U -C glucose 
into glycogen in rat diaphragm and glycogen content j_n vitro 
(- )Kpicatechin, when incubated with rat diaphragm causes 
14 
an increase in glycogen content as well as incorporat ion ol Li -(, 
glucose into glycogen of ra t diaphragm n± v i t ro in a dose dependent 
14 
manner. Kinetic s tud i e s show that the incorporation of U -C glucose 
into glycogen of ra t diaphragm is l inear upto 1 hour. 
( i i i ) Effect of ( - )epicatechin on l i p o l y s i s in epidymal fat pads 
i n v i t ro 
Lipo lys i s induced by 1.5 mM theophyl l ine in fat pads is 
i nh ib i t ed (61%) in the presence of 1 mM ( -)epicatechin as compared 
to 74% inh ib i t ion obse rved in the presence of 1 mil insulin. 
125 ( i v ) Effect of ( - )epicatechin on the binding of I-insulin to 
the l i v e r ce l l plasma membrane 
Competi t ive binding exper iments between ( - )ep ica tech in 
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and I - insu l in , does not show any significant change in the binding 
125 
of I - insul in to the l i v e r membrane indicat ing that the insulin 
l ike p r o p e r t i e s of the flavonoid are not due to i t s shar ing of the 
binding s i t e with insul in . 
( i v ) Effect of ( - )epicatechin on i s le t cAMP content 
The effect of ( - ) ep ica t ech in was s tud ied in the presence 
of 2 and 20 mM glucose concentrat ions and 200, 400, 600,800 and 
1000 uM ( - ) ep i ca t ech in in the medium. ( - J l ip ica tcchin caused a 
significant and dose dependent increase in i s le t cAMI1 content both 
at 2 and 20 mM glucose concentrat ion. 
( v ) Effect of age on ( - )epicatechin stimulated insulin release from i s l e t s 
of Langerhans in vitro 
At s t imula tory arid non-st imulatory concentrat ions of glucose 
in medium, ( - ) ep i ca t ech in (1 mM) st imulated the r e l ease of insulin 
qui te s ign i f i can t ly . However, (- )epicatechin and glucose s t imulated 
insul in r e l e a s e decreased with the increase of the an ima l ' s age . 
i. 
(v i ) Effect of ( - )epicatechin on cathepsin B ac t iv i ty in i s l e t s of Langer-
hans in v i tro 
Incubation of ra t i s l e t s with 1 mM ( - ) ep i ca t ech in for 2 
h r s caused 2.26 fold s t imulat ion in the i s l e t s ca theps in B a c t i v i t y 
over the con t ro l . 
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( v i i ) ( - )Epicatechin stimulated conversion of proinsulin to insulin and 
effect of age thereon 
Incubation of i s l e t s of Langerhans in K r e b ' s Ringer b i c a r -
14 
bonate medium containing 50 uCi C-leucine, and subsequent fract ion-
ation by passing through sephadex G-50 column (1.5x55 cm) gives 
d i s t inc t peaks of proinsul in (P) and insulin ( I ) . Proinsulin was 
cha rac t e r i zed by i t s conversion to insulin by ca theps in B, it was 
found that age has a pronounced effect on ( - )op ica tech in mediated 
transformation of pro insul in . The conversion of proinsul in to insulin 
in the case of 1 month old r a t s was found to be about {.)\ more 
as compared to the conversion in the case of 12 month old r a t s . 
II. Coleonol 
( i ) Effect of coloenol on insulin release _in v i tro 
Coleonol enhances the re lease of insulin from i s l e t s of 
Langerhans in v i t r o in the presence of 5.6 mM glucose in the medium, 
while in the medium containing non-s t imula tory concentrat ion of 
glucose, no effect on insulin r e l e a se has been o b s e r v e d . Stimulation 
of insul in r e l e a se has been obse rved upto 3 uM concentration of 
coleonol. 
( i i ) Effect of coleonol on glucagon re lease jin v i tro 
Coleonol has been found to s t imula te the r e l e a s e of glucagon 
from i s l e t s of Langerhans ijn v i t r o . Stimulation of glucagon re lease 
is much h ighe r than the r e l e a s e of insulin s t imula ted by coleonol 
in v i t r o . 
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( i i i ) Effect of coleonol feeding on serum insulin and glucagon leve l 
Coleonol feeding caused a significant increase in the serum 
insulin and glucagon l e v e l s . Increase in the serum glucagon level 
has been found to be much grea ter than the serum insulin level 
af ter coleonol feeding. 
i v ) Effect of coleonol on rat l i ver glycogen and gluconeogenic enzymes 
in v ivo 
Feeding of coleonol in normal r a t s causes a significant 
deple t ion of l i v e r glycogen (40%) and increase in the a c t i v i t i e s 
of gluconeogenic enzymes (Glucoso-6-phospha tasc ) . 
(v) Effect of coleonol on oxygen-uptake by l iver mitochondria 
Cu-uptake s tud ies in oxygraph show that feeding of coleonol 
increases CL-consumption by l i v e r mitochondria , showing an increased 
metabolic r a t . 
( v i ) Effect of coleonol on i s l e t enzymes in v ivo 
Feeding of coleonol in normal r a t s causes a significant 
s t imulat ion in the a c t i v i t y of i s l e t gluconeogenic enzyme, glucose-
6 -phospha t a se and lysosomal enzyme, ca theps in B. 
III.CCK-4 
( i ) Effect of synthet ic analogues of C-terminal tetrapeptide amide of 
cholecystokinin on insulin and glucagon release from the i s l e t s 
in v i tro 
The cholecys tok in in s t imulated the secre t ion of pancrea t ic 
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hormones in a dose - r e l a t ed manner. CCK-4 was by for the most 
potent p e p t i d e . Even at the lowest concentration of 10 M, CCK-4 
was a powerful secre tagogue. The syn the t i c pep t i de s with C-terminal 
modifications such as removal of t ryp tophan (CCK-4), extension 
by glycine (CCK-5, gas t r in pen tapep t ide) reduced the secre t ion 
of pancrea t ic hormones. Pep t ides with N-terminal modifications 
were syn thes ized by subs t i tu t ions of L-Pro , ^ P r o , D-Pro or Thz 
(Th iazo l id ine -4 -ca rboxy l i c ac id) in place of Trp at posi t ion 1 of 
the CCK-4 molecule. 
Subst i tu t ions of L-Pro , ^ P r o and Thz at posi t ion 1 of CCK-4 
molecule reduced the insulin re leas ing a c t i v i t y of CCK-4 analogues 
as compared to CCK-4. However, these analogues have no effect 
on glucagon r e l e a s e . Subst i tut ion of D-Pro at posi t ion I of CCK-4 
molecule and N-methylat ion of Phe res idue resu l t ed in the s t imu-
lat ion of insulin r e l ea se and inh ib i t ion of glucagon r e l e a s e . 
( i i ) Effect of stimulatory concentration of glucose on CCK-4 and i t s 
analogues stimulated insulin and glucagon re lease in v i tro 
CCK-4 and i t s syn the t i c analogues were found to be in-
creas ing the r e l e a s e of insulin at basal as well as s t imula tory 
concentrat ions of glucose. Synthet ic analogues of CCK-4 were found 
to have an a d d i t i v e effect on insulin r e l e a s e at s t imula to ry concent-
ra t ion of glucose in the incubation medium. CCK-4 analogues (DPMAP 
fi LPMAP) have i n h i b i t o r y effect on glucagon r e l ea s e at 20 mM glucose 
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Effect of age on CCK-4 stimulated r e l ea se of insulin from i s l e t s 
of Langerhans in vitro 
At basal concentrat ion of glucose in the medium insulin 
r e l e a se from 1 and 12 months old rat i s l e t s was not s igni f icant ly 
d i f ferent . However, aged rat i s l e t s re leased less insulin in r e s -
ponse to CCK-4, DPMAP 6 !,!'\1AP compared to that from younger 
ones. 
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